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BALF broncho-alveolar lavage fluid
BSA bovine serum albumin
CHO carbohydrate
COPD chronic obstructive pulmonary disease
Cy3 cyanine 3
DAB 3,3' -diaminobenzidine tetrahydrachloride
EDTA ethylenediaminetetraacetic acid
EGTA ethylene glycol-bis((3-aminoethyl ether)-N,N,N',N,-tetraacetic
acid
ELISA enzyme-linked immunosorbent assay
ENE equine neutrophil elastase
FCS foetal calf serum
FITC fluorescein isothiocyanate
His histidine
HNE human neutrophil elastase






LRT lower respiratory tract
LPS lipopolysaccharide
mAb monoclonal antibody
MOPC mineral oil plasmacytoma
MPBS dried skimmed milk in PBS
Mr relative molecular weight
MW molecular weight
MWCO molecular weight cut off
NE neutrophil elastase
NGS normal goat serum
NSS normal sheep serum
OD optical density
PAGE polyacrylamide gel electrophoresis




PELF pulmonary epithelial lining fluid
PNGase F peptide N-Glycosidase F
RSL reactive site loop
RZ protein to enzyme ratio
SDS sodium dodecylsulphate
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SEC serpin enzyme complex
Ser serine
SERPIN serine proteinase inhibitor
Spi serine proteinase inhibitor
Tb Thoroughbred





Pulmonary emphysema in the horse in response to lung disorders associated with an
influx of neutrophils, such as chronic obstructive pulmonary disease (COPD), results
in a restricted peribronchiolar pattern of tissue damage. Humans, in contrast, have a
more extensive centrilobular pattern of emphysema in similar neutrophil associated
lung disorders. The major cause of pulmonary emphysema has been shown to be
excessive or unregulated neutrophil elastase activity which has led to the development
of the 'proteinase:anti-proteinase theory of lung disease'. To evaluate the
proteinase:antiproteinase balance in the horse in order to compare it to that found for
human API some aspects of equine neutrophil elastase (ENE) and its main regulator
in the lower respiratory tract, equine alpha-1-proteinase inhibitor (API), have been
investigated.
Mouse monoclonal and sheep polyclonal antibodies specific to equine API were raised
and used to show by immunohistochemistry that the distribution of equine API was
very similar to that of the previously known distribution for human API. The major
difference between the two species was that equine hepatocytes and bile ductules
showed extensive and often intense positive staining for equine API which has not
been demonstrated in equivalent human tissues.
Sheep polyclonal antibodies specific to ENE 2A, the most abundant ENE found in
equine neutrophils, were raised and used to show that ENE 2A had a granular
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distribution confined to the cytoplasm of neutrophils and that each neutrophil
contained 0.813 ± 0.054 pg (mean ± SEM) of ENE2A. In contrast equine API had a
uniform non-granular cytoplasmic distribution and each neutrophil contained 0.021 ±
0.003 pg ofequine API.
In dynamic studies of Percoll purified equine peripheral blood neutrophils a positive
correlation existed between the total superoxide anions (SOA) generated and release
of ENE 2A when stimulated with zymosan activated serum over 90 minutes. These
kinetic data suggest that SOA generation may have the potential to prolong the
activity of ENE 2A in the neutrophil's immediate microenvironment by promoting
oxidative inactivation of API thereby enhancing the neutrophil's contribution to local
host tissue damage. Both these secretory mechanisms were dependent upon
extracellular cations.
These findings suggest that the difference in anatomical distribution of pulmonary
emphysema in horses and humans is probably due to a higher concentration of plasma
derived equine API in pulmonary epithelial lining fluid. This, combined with the
presence of oxidation resistant serine proteinase inhibitor (Spi) proteins, creates a
more efficient antiproteinase screen in the neutrophil micro-environment in equine
pulmonary tissues resulting in more effective inhibition of unwanted neutrophil




The ability of serum to inhibit proteolysis was noted over a century ago by Camus and
Gley in 1897; they noticed that canine serum decreased the activities of pepsin and
trypsin on milk proteins and albumin. However, it was the discovery of a link between
a serum dysproteinaemia, unregulated neutrophil elastase activity and the
development of pulmonary emphysema in humans (Laurell and Eriksson, 1963;
Eriksson, 1964; Janoff and Scherer, 1968; Hayes et al 1975) that stimulated more
intense medical research into proteolytic enzymes and their inhibitors.
1.1 Functional Importance of Proteolytic Enzymes
Protein metabolism and its regulation is one of the fundamental properties necessary
for the maintenance of life. Proteolytic enzymes and their regulators are vital for
digestion, blood coagulation, complement activation, host defence and a vast array of
other processes (Bieth, 1986; Potempa et al 1994). The various specificities, rates and
durations of these processes are all determined by proteolytic enzymes which are
categorised broadly into 4 classes dependent upon their active site structure: serine,
cysteine, aspartic and metallo-proteinases (Neurath, 1996) and their respective
inhibitors. The name of each group refers to the key amino acid residue or component
(i.e. zinc in metallo-proteinases) of the active site of the enzyme which dictates
enzyme activity and specificity. The active site, which usually lies in a cleft on the
surface of the molecule, consists of a unique spatial arrangement of amino acid
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residues which confer on the enzyme the ability to hydrolyse peptide bonds of certain
amino acid sequences. The nomenclature of the subsites varies about the named
catalytic group (e.g. serine, cysteine etc.) such that they are numbered Si, S2, etc.
away from the catalytic site towards the N-terminus and Sf, S2' etc. towards the C-
terminus. The corresponding alignment on any peptide substrate is denoted by P,
hence Si aligns with Pi, S2 with P2 and so forth (Barrett, 1986). The conformation of
the whole enzyme depicts whether the active site can be brought into close association
with these peptides both physically and electrostatically. In this way the substrate
specificity ofan enzyme is determined.
1.2 Serine Proteinases
The serine proteinases are the most studied family of mammalian proteolytic enzymes
and probably the most evolutionary successful as they are the most numerous and
diverse group (Barrett, 1986). Historically, studies began with the digestive enzymes
of the pancreas (especially trypsin and pancreatic elastase) because of the relative ease
of obtaining reasonable quantities of the enzymes and the direct application of the
findings to an observable process such as digestion. The active site of serine
proteinases is found typically on a surface depression rather than in a cleft like the
other families ofproteinases (Fersht, 1985).
1.2.1 Mechanism ofAction
Peptide and synthetic ester substrates are hydrolysed by the acyl-enzyme mechanism.
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The enzyme and substrate initially form a non-covalent enzyme-substrate complex due
to spatial conformity and physical forces of attraction in the enzyme's specificity
pocket (i.e. electrostatic, Van der Waals, etc.) (Branden and Tooze, 1991). The
serine-195 hydroxyl group of the proteinase which has an induced negative charge
then mounts a neucleophilic attack on the induced positively charged carbonyl carbon
atom of the substrate. This is catalysed by the histidine-57 residue acting as a general
base and results in a tetrahedral intermediate which in turn becomes an imidazolium
ion which then breaks down by acid catalysis to an acyl-enzyme intermediate and
amine product (first peptide product). The proton of the serine hydroxyl group is
transferred to the leaving amine group. The acyl-enzyme is then hydrolysed by the
reverse reaction pathway of acylation, however, a water molecule instead of the serine
residue is now the attacking nucleophile, this allows release of the second peptide
product and regeneration of enzymatic activity (Fersht, 1985; Barrett, 1986; Polgar,
1990).
1.3 Human Neutrophil Elastase
Human neutrophil elastase (HNE) is the most studied non-digestive mammalian serine
proteinase due to its role in several well documented pathological conditions (Janoff,
1985b). Research has revealed that neutrophil elastase (NE) is essential for normal
host defence and the advantages of its presence far outweigh those of its absence
(Dale et al 1972).
A proteinase may only be called an 'elastase' if it is capable of solubilising mature
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cross-linked elastin as HNE does, but this does not imply that elastases are specific for
elastin as they hydrolyse many other proteins (Bieth, 1986). Although the most
abundant form of non-pancreatic elastase is neutrophil elastase, elastases have also
been found in peripheral blood monocytes and alveolar macrophages and are
collectively referred to as leukocyte elastases (Bieth, 1986; Campbell et al 1989). The
first pathological process HNE was associated with was vascular endothelial damage
(JanofF and Scherer, 1968). The link between its excessive and/or unregulated activity
with pulmonary emphysema was not confirmed experimentally until much later (Hayes
et al 1975; JanofFet al 1977).
1.3.1 Structure
Human neutrophil elastase is a 29kDa, 218 amino acid, single chain globular
glycoprotein stabilised by 4 disulphide bonds linking eight half cysteine residues
(Sinha et al 1987; Crystal, 1996). The presence of 19 arginine residues, which
considerably outweigh the properties of the eight acidic residues, are responsible for
the highly basic nature of HNE (Crystal, 1996). All but one of the arginine residues
are located on the surface of the molecule in a horse-shoe like manner around the
active site. This arrangement contributes to the enzymes preference for binding to
linear sulphated polysaccharides and to the negatively charged proteoglycan matrix of
the neutrophil storage granule (Crystal, 1996). Two asparagine linked carbohydrate
(CHO) side chains (Asn-95 and Asn-144) are present and variations in these account
for the three or four isoforms of HNE found on gel electrophoresis in some studies
(Baugh and Travis, 1976; Vanhalbeek et al 1988; Watorek et al 1993). Both CHO
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side chains point away from the active site and into the surrounding milieu and so are
unlikely to interfere with the binding of smaller protein substrates or inhibitors,
however, they may become entangled within the extended elastin network of the
extracellular matrix (Crystal, 1996).
1.3.2 Mechanisms ofElastase Release From Neutrophils
Active release of intracellular stores of HNE from neutrophils occurs by two main
pathways; (1) the release by fusion of azurophilic storage granules with plasmalemma
which is committed to, or has already formed, phagocytic vacuoles and (2)
phagocytosis independent release of azurophilic storage granule contents by fusion
with areas of the cell plasma membrane that are not involved in phagocytic uptake
(reviewed in Baggiolini and Dewald, 1984). Passive release ofHNE occurs due to cell
death and disintegration (necrosis) of the neutrophil usually at sites of infection.
Neutrophil elastase is also found in small amounts in close association with the cell
membrane facilitating diapedesis (Henson and Johnston, 1987).
1.3.3 Gene Expression and Protein Localisation
The HNE gene has been located on chromosome 11 at ql4 and consists of 5 exons
and 3 introns (Takahashi et al 1988b) and is only expressed in bone marrow
myelocytic precursor cells (Takahashi et al 1988a), especially promyelocytes (Fouret
et al 1989). Expression of the gene is regulated primarily at the level of gene
transcription (Yoshimura and Crystal, 1992). The coding exons of the NE gene
predict a primary translation product of 267 residues which includes 29 residue N-
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terminal and 20 residue C-terminal precursor peptides. Further analysis of the N-
terminal peptide sequence reveals a 27 residue 'pre' signal peptide and a 'proN'
dipeptide, similar to that of other blood cell lysosomal proteases (Takahashi et al
1988b). This 'proN' peptide would allow intracellular transport and temporary storage
prior to being packaged into the primary (azurophilic) granules of the cytoplasm of
neutrophils without the risk of intracellular proteolysis (Crystal, 1996). In normal
adults each mature neutrophil contains about 1.1pg of HNE (Campbell et al 1989)
stored in the primary cytoplasmic granules (Dewald et al 1975; Cramer et al 1989).
1.3.4 Physiological Functions
Human neutrophil elastase is a neutral protease, with a very catholic consumption in
terms of substrates, which can be rapidly transported to any part of the body via the
highly mobile peripheral blood neutrophil in response to chemotactic inflammatory
mediators (Bieth, 1986). This mobility is greatly dependent upon HNE itself as it is
involved in neutrophil migration through vascular endothelium to gain access to extra-
vascular compartments (Henson and Johnston, 1987). Large amounts of elastase can
be rapidly recruited into areas of inflammation to assist host defence and in
remodelling of damaged tissues through its ability to cleave many components of the
extracellular matrix. Platelet activation (Selak, 1992), oxygen independent bactericidal
activity (Ganz et al 1987) and digestion of micro-organisms and other material within
the phagolysosome (JanofF, 1985b) also require elastase activity (JanofF and Scherer,
1968; Mainardi et al 1980; Heck et al 1985; Sinha et al 1987; Bieth, 1986). Much oF
HNE role in host deFence has been elucidated through the study of Chediak-Higashi
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syndrome, a rare autosomal recessive condition of humans where the neutrophils are
deficient in NE resulting in increased susceptibility to pyogenic infections (Dale et al
1972; Ganz et al 1988).
1.3.5 Regulation ofHNEActivity
In the healthy state, the activities of HNE in the execution of host defence and tissue
remodelling are precisely controlled. Extracellular and intracellular HNE is regulated
by serine proteinase inhibitors such as alpha-1-proteinase inhibitor (API) (Gadek et al
1981b; duBois et al 1991; Mason et al 1991) and secretory leukocyte proteinase
inhibitor (SLPI) (Sallenave et al 1997a). Similarly, a2-macroglobulin, a plasma
protein of high molecular weight which can inhibit proteinases from many different
families, plays a role in the regulation of HNE (Travis and Salvesen, 1983). In
addition to inhibition of free elastase, phagocytosis of apoptotic neutrophils protects
tissues from the potentially harmful consequences of exposure to the contents of
effete cells (Savill et al 1993). Activated cells of the monocyte/macrophage cell line
are the main phagocytes involved in this process but other cells such as glomerular
mesangial cells have also been shown to phagocytose apoptotic neutrophils (Duvall et
al 1985; Savill et al 1989; Savill et al 1992).
1.3.6 Pathology Associated With Neutrophil Elastase
Due to the extensive range of substrates which HNE hydrolyses (Bieth, 1986), any
prolonged breakdown in regulation will ultimately lead to unwanted host tissue
damage. It has been shown that a so-called marginated pool of neutrophils exists in
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the lung, which is in a dynamic equilibrium with the circulating pool, and is released
into the main circulation when cardiac output is increased by adrenaline and is
conserved when output subsequently falls (reviewed in Rossi and Hellewell, 1994).
This suggests that the lung plays a significant role in neutrophil kinetics despite
containing tissues which are highly sensitive to the action of its elastinolytic enzymes.
The sequestration of large numbers of neutrophils in the pulmonary circulation is
probably a response to the susceptibility for microbial invasion of the large surface
area of the lungs vital to gaseous exchange. However, this large pool of neutrophils
means that the lung is also highly susceptible to host induced tissue damage and
emphysema.
Pulmonary emphysema in humans is predominantly associated with cigarette smoking
and the accumulation and degranulation of neutrophils in the lung. This may be the
result of 'frustrated phagocytosis' in the neutrophils and specific activation of them,
either directly from inhaled smoke particles or via inflammatory mediators (Travis et
al 1994; Gadek and Pacht, 1996a). Some of these inflammatory mediators are
released by alveolar macrophages which make up the largest percentage of resident
cells in the airways and contain a metalloelastase which is also capable of solubihsing
mature cross-linked elastin (Snider et al 1991). Human NE has been immunolocalised
adjacent to elastin fibres in emphysematous lungs but not in samples of normal
pulmonary tissue (Damiano et al 1986) suggesting that it is a major factor in the
pathogenesis of the disease.
20
Other diseases in which HNE has been shown to play a significant pathogenic role are
cystic fibrosis (Suter et al 1986; Suter and Chevallier, 1991), adult respiratory distress
syndrome (Gadek and Pacht, 1996b), glomerulonephritis (Stauber et al 1994),
vascular endothelial damage (Smedly et al 1986) and rheumatoid arthritis (Roughley
and Barrett, 1977; Travis et al 1980; Matheson et al 1982).
Failure of HNE regulation can come about by two basic mechanisms; a fault in the
normal proteinase inhibitory function (API deficiency, Perlmutter, 1996, see below),
or overwhelming of the normal antiproteinase screen by excessive proteolytic activity.
These two mechanisms have led to the delicate balance between these two factors
being referred to as the 'proteinase:antiproteinase theory' of disease (Shapiro, 1995).
1.4 Equine Neutrophil Elastase
Initial studies of equine neutrophil contents found three proteinases present with
elastinolytic properties which were named Proteinase 1, 2A and 2B (Dubin et al 1976;
Potempa, 1982). Subsequent studies, including those in our own laboratory have,
however, failed to support these findings as only two proteinases which will be
referred to as equine neutrophil elastase (ENE) 2A and 2B have been purified from
equine neutrophils (Koj et al 1976; Scudamore et al 1993; Pemberton et al 1993;
Dubin et al 1994).
The amount of total ENE present, as measured by enzyme activity, has been
previously estimated as 0.4pg/equine neutrophil in a ratio of 3:1 ENE 2A:ENE 2B
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respectively (Von Fellenberg et al 1985; Dubin and Koj, 1986). This suggests that the
amount of elastase present in horse neutrophils is a little over a third that in human
neutrophils (Campbell et al 1989).
1.4.1 Structure and Biochemical Properties
Both equine elastases are neutral proteases and their biochemical properties are
summarised in Table 1.1. The structure ofneither protein has been fully elucidated but
amino acid sequencing of the N-terminus, including the substrate binding regions,
indicates that the two elastases show a 71% sequence identity to each other. When
compared to HNE, ENE2A and ENE2B show a 68% and 86% sequence identity
respectively. Within the first 34 amino acid residues of the N-terminus ENE2B differs
from HNE in only three positions (Dubin et al 1994).
Property Elastase 2A Elastase 2B Human
Elastase
Relative molecular weight (Mr) 24500 20500 29000
Polypeptide chains 1 1 1
Isoenzymes 1 1 3
Isoelectric point pi 8,8 >10 >9
pH optimum of activity
a) casein 7.4 7.4 7.0
b) elastin 7-10 7
Active centre Ser-His Ser-His Ser-His
Table 1.1 - Properties of elastases from horse and human leukocytes. Pooled data
from Dewald et al 1975; Dubin et al 1976; Baugh and Travis, 1976; Bieth, 1986;
Sinha et al 1987; Watorek et al 1993.
Both forms of equine elastase have identical specificity when exposed to the oxidised
insulin B-chain by preferentially attacking the peptide bonds with small aliphatic
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amino acids (valine and alanine) at their PI site (Dubin et al 1994). Despite this, ENE
2B displays a seven fold higher elastinolytic activity than HNE, which has a similar
elastinolytic activity to that of ENE 2A (Potempa et al 1985). These differences
probably stem from amino acid residue variations in the primary structure causing
alterations to spatial conformity between whole elastase and elastin molecules, and to
electrostatic forces on secondary binding sites and on the active sites on the three
respective enzymes. Thus, although the amino acid residues around the reactive site
are critical for determination of substrate specificity and kinetics of inhibition they are
moderated to some extent by the overall tertiary structure of the enzyme (Dubin et al
1994).
1.4.2 Physiological Functions and Pathology
Direct knowledge of the physiological and pathological roles of equine elastases has
not been documented therefore all assumptions about their roles have been made by
analogy with human data (Dubin et al 1994). With respect to disease, the horse was
originally considered to be the only mammal, besides man, that suffered from
spontaneous pulmonary emphysema as a result of chronic obstructive pulmonary
disease (Gillespie and Tyler, 1969; Gerber, 1973). Chronic obstructive pulmonary
disease (COPD) in horses is a cause of great economic loss being the most common
pulmonary disease of the adult horse in temperate climates (Freeman et al 1993;
Dixon et al 1995a). The aetiology/pathophysiology of pulmonary emphysematous
changes found in advanced COPD was assumed to be excessive and/or unregulated
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ENE activity (Dubin et al 1994) as occurs in human pulmonary emphysema (Laurell
and Eriksson, 1963; Gadek et al 1981a).
1.5 The Importance of Proteolytic Regulation
The regulation of proteolytic enzymes in tissues by endogenous inhibitors is a critical
requirement for maintenance of homeostasis without which, extensive host tissue
damage would occur. These inhibitors are proteins and glycoproteins found primarily
in the blood plasma (representing over 10% of total plasma proteins) although
increasing numbers of intracellular inhibitors are being identified. Several classes of
proteinase inhibitors exist to regulate the activity of the different classes of proteolytic
enzymes present. One superfamily of inhibitors, the serpins (SERine Proteinase
INhibitors), predominates with over 60 known members which are found in animals,
plants and viruses (though not Prokaryotes) (Potempa et al 1994; Carrell and Stein,
1996).
1.6 Serine Proteinase Inhibitors
It is estimated that serpins have been undergoing divergent evolution for some 200
million years from a common ancestral inhibitor (Carrell et al 1986; Goodwin et al
1996). Their common features are a conserved tertiary structure containing a stressed
loop present in an exposed position near the C-terminus and a free N-terminal
segment both of which are available for peptide cleavage (Carrell et al 1986).
Although they are mainly involved with proteinase inhibition, they have also been
found to have many diverse functions such as hormone transportation, blood pressure
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regulation, tumour suppression, cell differentiation, protein folding, cell migration,
prohormone conversion and regulation of the complement cascade (reviewed in
Potempa et al 1994).
1.6.1 General Serpin Structure
The extracellular serpin superfamily have molecular masses ranging from 45000 to
70000 and contain varying amounts of CHO and disulphide bonds. The CHO side
chains appear to play little role in the specific activity of individual serpins but have a
general function of increasing their plasma half life (West, 1986; Travis et al 1990;
Guzdek et al 1990; Mast et al 1990). The critical structure of those serpins which
have retained their proteolytic inhibitory activity is the presence of a mobile reactive
site loop (RSL) (Travis et al 1990; Lawrence et al 1994) which acts as a bait region
for the respective proteinase. Minor changes in the amino acid sequence of the RSL
have profound changes on the binding specificities and/or inhibitory functions of these
proteins. The alpha-1-proteinase inhibitor mutation PiMPjttsburgh in which the PI residue
methionine-358 is replaced by an arginine residue results in the inhibitory specificity of
the molecule changing from HNE to thrombin effecting a fatal bleeding disorder in
humans (Owen et al 1983). The most studied member of the inhibitory serpins is
alpha-1-proteinase inhibitor (API) whose main role appears to be the regulation of
neutrophil elastase, especially in the lower respiratory tract (Gadek et al 1981a;
Janoff, 1985a;).
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1.7 Human Alpha-l-Proteinase Inhibitor
1.7.1 Historical Context
Alpha-1-proteinase inhibitor was discovered when it was realised that a hereditary
disorder resulting in the development of premature emphysema was linked to a
decrease in the a 1-globulin band of protein on one dimensional agarose gel
electrophoresis of human serum (Laurell and Eriksson, 1963). It had previously been
shown that 90% of the a1-globulin band consisted of a single protein which could
inhibit the enzymatic properties of trypsin, hence the protein was initially named
alpha-1-antitrypsin (Jacobsson, 1955). It was not until pulmonary emphysema was
shown to be induced by intratracheal instillation of proteolytic enzymes, especially
purified HNE, that the true target enzyme ofAPI was determined (Elayes et al 1975;
Janolf, 1985b). This lead to the realisation that although alpha-1-antitrypsin does
indeed inhibit trypsin, it is a misnomer in that the physiological target enzyme is
neutrophil elastase. As a result the term alpha-1-proteinase inhibitor is now preferred.
1.7.2 Alpha-1-Proteinase Inhibitor Gene Expression
The human API gene is located on the q arm of chromosome 14 (Sefton et al 1990),
is 12.2 kb in length and comprises of seven exons (Crystal, 1989). The protein coding
region is within exons II-V and encodes for a 418 amino acid product including a 24
amino acid signal peptide from exon II (Long et al 1984) which enables endoplasmic
transport and processing in the Golgi apparatus prior to secretion into the plasma
(Brantly et al 1988). The encoding for the Pi methionine-358 residue on the reactive
site loop of API is within exon V (Loebermann et al 1984). Two of the three
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glycosylation sites are encoded in exon II, the other in exon III. The API gene is
expressed in a variety of cells; peripheral blood monocytes, pulmonary and breast
macrophages (Perlmutter et al 1985), neutrophils (Paakko et al 1996), alveolar
epithelial cells (Yenembre et al 1994; Cichy et al 1997), intestinal epithelium
(Molmenti et al 1993) and cornea (Twining et al 1994), but most abundantly in
hepatocytes (Alper et al 1980) which contain 200 times more mRNA than other cells
(Rogers et al 1983). Transcription of the API gene results in three major mRNA
products, 1.6, 1.8 and 2.0kb in length. The shortest, 1.6kb, mRNA is exclusively
found in hepatocytes and enterocytes with the transcription start site located within
exon IC (Perlino et al 1987). The two longer mRNA products, 1.8 and 2.0kb, found
in mononuclear phagocytes and other non-hepatic, non-enterocytic API producing
cells, are in exons IA and IB respectively, providing two alternative transcription start
sites (Hafeez et al 1992). The protein product from all these mRNA species is
however identical. These variable transcription start sites may explain why different
API producing cells respond differently in terms of API synthesis to identical stimuli
(Koj et al 1991; Sallenave et al 1997b).
Over 2g ofAPI are secreted daily into human plasma (Jeppsson et al 1978; Jones et al
1978) to maintain a basal concentration of l-1.3mg/ml in the normal adult, virtually all
of this active circulating plasma API being derived from hepatic synthesis (Travis and
Salvesen, 1983; Carrell, 1986). As API is one of the acute phase inflammatory
proteins the plasma concentration can rise rapidly, up to four times the basal level in
response to liberated inflammatory mediators (Dickson and Alper, 1974; Perlmutter,
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1996). This rise is due to an increase in actual synthesis, mainly in the liver and not
just release of preformed stored protein (Schulze et al 1990). As might be expected
for an acute phase protein, production is upregulated by IL-6 in hepatocytes and
blood monocytes (Perlmutter et al 1989; Hafeez et al 1992). Interestingly, during
basal conditions, hepatocyte API transcription is from exon IC, but during
upregulation by IL-6 transcription also occurs from exon IA as in non-hepatic, non-
enterocytic cell types (Hafeez et al 1992). The IL-6 induced API upregulation in
hepatocytes also appears resistant to corticosteroid inhibition (Castell et al 1988;
Perlmutter et al 1989; Hafeez et al 1992). In monocytes API synthesis is upregulated
by neutrophil elastase (NE) and lipopolysaccharide (LPS) in an additive manner
(Perlmutter and Punsal, 1988). Neutrophil elastase upregulates synthesis and LPS by
an as yet unknown mechanism (Perlmutter et al 1988) (Perlmutter and Punsal, 1988).
1.7.3 Structure
Alpha-1-proteinase inhibitor is a 52 kDa, single chain, 394 amino acid globular
glycoprotein with three externally located asparagine linked CHO side chains (Carrell
et al 1982; Loebermann et al 1984; Eriksson, 1996). The side chains, located at Asn-
46, Asn-83 and Asn-247, are variably biantennary or triantennary complex
carbohydrates and therefore result in microheterogeneity visible on gel electrophoresis
(Carrell and Owen, 1979; Vaughan and Carrell, 1981; Mackiewicz et al 1993). The
CHO side chains present in the native glycosylated form of API somehow prevent
renal filtration, resulting in a plasma half life of 5 days compared to 2 days for
unglycosylated recombinant API (Mast et al 1990). Incompletely glycosylated
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variants of API are found to have identical second order association rates with HNE
when compared to native API but are found to be more heat sensitive than the mature
protein (Guzdek et al 1990). These findings suggest that the CHO side chains are of
little importance to the proteinase inhibitory function of API but play key roles in the
general stabilisation of the protein molecule and the duration of its plasma half fife.
The single amino acid chain is formed into nine a-helices (A-I) and three (3-pleated
sheets (A-C) which are arranged in such a way as to hold the reactive centre loop (the
forth strand of (3-sheet A) out from the rest of the molecule. The exposed reactive site
loop acts as a 'bait region' (Carrell el al 1986) mimicking a peptide sequence
susceptible to attack by the active site of serine proteinases, especially HNE. The 15
amino acid sequence of the RSL is critical to the specificity, rate of association and
inhibition of target proteinases (Olson et al 1995; Djie et al 1996; Elliott et al 1996a).
Full primary, secondary and tertiary structures of human API have been elucidated
and the Pi, Pf residues, which are located on the RSL, are methione-358 and serine-
359 respectively. These two residues are held such that their peptide bond is greatly
distorted resulting in the native inhibitor molecule being in a 'stressed' configuration
(Figure 1.1) (Loebermann et al 1984).
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ALPHA-1-PROTEINASE INHIBITOR NEUTROPHIL ELASTASE
Figure 1.1 - Diagrammatic representation of alpha-1-proteinase inhibitor and
neutrophil elastase. Grey ellipses represent asparaginyl (Asn) linked CHO side chains
(numbers equal position of Asn on protein chain). Met358 and Ser359 are the P, and
Pi' residues respectively situated on the reactive site loop of API. The red ellipse
depicts the surface depression where the active site ofNE is situated.
A critical feature of the serpins that separates them from families of smaller molecular
weight inhibitors is the conformational polymorphism of the RSL, which, along with
at least two (3-pleated sheets, change conformation during the reaction with
proteinases. It has been suggested that this property is responsible for the unique
inhibitory mechanism of serpins and also the ability to form dimers and polymers
(Wright, 1996).
1.7.4 Mechanism ofInhibition
The mobile RSL ofAPI mimics the substrates of HNE so that the two molecules are
strongly attracted to each other (kass = 107 M"1 s"1) by spatial conformity, hydrogen
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bonds, electrostatic and Van de Waals forces (Branden and Tooze, 1991; Elliott et al
1996a). This is followed by the y-OH group ofHNE making a neucleophilic attack on
the scissile Pi Met-358, Pf Ser-359 peptide bond of the RSL as would occur in a
normal serine proteinase:peptide interaction. What happens next is not completely
understood but it is thought that the two molecules form a tetrahedral intermediate
which then follows one of two possible paths. The proteinase may, in some cases,
cleave the inhibitor and dissociate from it resulting in active proteinase and inactive
inhibitor, or, as occurs in the majority of cases, form an SDS stable enzyme:inhibitor
complex possibly involving formation of a covalent bond via an acyl-enzyme structure
(Wright, 1996).
Cleavage of the RSL produces a great conformational change in API such that the
two once adjacent amino acid residues, Pi and Pf, are moved to the opposite poles of
the molecule 69A apart, however, it is very controversial as to whether this occurs in
stable proteinase:inhibitor complexes (Mast et al 1991b). Uncomplexed API in which
proteolytic cleavage of the RSL has taken place results in increased heat stability of
the molecule suggesting the active inhibitory form is in an energetically stressed state
(Carrell et al 1986).
When HNE complexes with API, it does so in a pseudo-irreversible manner (Elliott et
al 1996a) in a 1:1 molar ratio (Travis and Salvesen, 1983). Both molecules are
inhibited when complexed and if dissociation does occur the resultant free API is
usually in the relaxed state due to cleavage of the RSL at the Pi-Pi' bond and thus
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unable to inhibit further HNE. For this reason API is known as a 'suicidal' inhibitor as
each molecule can only inhibit once (Wright, 1996). Alpha-1-proteinase inhibitor does
interact with other serine proteinases but with much slower association rates
suggesting that regulation of HNE activity is its primary inhibitory role (Table 1.2)
(Carrell et al 1986).
Serine proteinase Association rate constant (kass)
M-y1
Human neutrophil elastase 7x 107
Porcine pancreatic elastase 1 x 105
Porcine pancreatic trypsin 4x 104
Human thrombin 5 x 10'
Human kallikrein 7x10'
Human Factor Xa 2x 102
Human Factor XIa 7x 10'
Human Factor Xllf Nil
Human plasmin 2x 102
Human cathepsin G 4x 105
Table 1.2 - Variation in association rate ofAPI with different serine proteinases (from
Carrell and Boswell, 1986).
Any resultant APEserine proteinase complex is recognised by the serpin-enzyme
complex (SEC) receptor (Pizzo et al 1988) located on hepatocytes, Kupffer cells and
activated monocytes and macrophages (Perlmutter et al 1990a) which internalise and
degrade it (Perlmutter et al 1990b; Joslin et al 1991a). This receptor is not specific for
APEHNE complexes but also binds to antichymotrypsin, CI inhibitor, antithrombin
III and heparin cofactor II when complexed with serine proteinases (Pizzo et al 1988;
Joslin et al 1991b). In addition several tachykinins such as substance P, amyloid-P
peptide and bombesin have been also found to bind to the SEC receptor (Joslin et al
1991b). The SEC receptor recognises a pentapeptide domain equivalent to amino acid
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residues 370-374 on API (Joslin et al 1991a) which has been shown to be conserved
in other serpins (Joslin et al 1992). Recent studies have also shown the involvement of
a low density lipoprotein in serpin:enzyme recognition, cellular internalisation and
degradation (Poller et al 1995; Kounnas et al 1996). Despite the controversy over the
precise mechanism of recognition it has been clearly demonstrated that serpin:enzyme
complexes are rapidly removed from the circulation with a half life of about 12
minutes (Pizzo et al 1988) compared to 5 days for native API (Jones et al 1978; Mast
et al 1990). Proteolytically inactivated inhibitors are also removed but less rapidly
than the complex (Mast et al 1991b).
The API:UNE complex has been shown to be biologically active in that it is a potent
chemoattractant for neutrophils (Banda et al 1988) and an upregulator of the API
gene in monocytes and macrophages suggesting a role in inflammatory signalling and
neutrophil activation (Perlmutter et al 1990a).
1.7.5 Oxidative and Proteolytic Inactivation ofAPI
The RSL of API, by virtue of its amino acid structure and physical accessibility, is
susceptible to both proteolytic and oxidative inactivation (Johnson and Travis, 1979;
Mast et al 1991a). The Pi Met-358 residue can be oxidised to methionine sulphoxide
by a host of different oxidants found in macrophages (Mast et al 1991a), neutrophils
(Ras et al 1992) and cigarette smoke (Travis et al 1980). Proteolytic cleavage of the
RSL can be brought about by matrix metalloproteinases (Mast et al 1991a),
neutrophil metalloproteinases (Ottonello et al 1994) and bacterial proteinases (Suter
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and Chevallier, 1991; Potempa et al 1991a). These mechanisms greatly reduce the
efficacy of API as an inhibitor and hence as a regulator of proteinases (Table 1.3)
(Matheson et al 1982). These two mechanisms may therefore be important in the
development ofpulmonary emphysema in API sufficient individuals.
Enzyme Native API Oxidised API
Human neutrophil elastase 6.5 x 107 3.1 x 104
Human chymotrypsin 5.5 x 106 1.0 x 106
Porcine pancreatic elastase 1.0 x 103 Zero
Human trypsin 1.1 x 104 3.0 x 103
Human plasmin 1.9 x 102 Zero
Table 1.3 - Association rate constants (kass M"'s"') of native and oxidised API with
serine proteinases (from Matheson et. al. 1982).
1.7.6 Deficiency and Disease
In man several normal genetic variants, which all have circulating plasma levels of
fully functional API within the standard range, are recognised and denoted as M due
to their middle position of migration on isoelectric focusing gels (Allen et al 1974).
However, there are at least 20 known API alleles associated with API plasma
deficiency and several different mechanisms by which these mutants manifest
themselves (Brantly et al 1988; Crystal et al 1989). The Z mutation, which was the
first to be discovered (Laurell and Eriksson, 1963), is responsible for more than 95%
of all the diagnosed cases of API deficiency (Brantly et al 1988). It is an autosomal
recessive genetic defect found in the descendants ofNorthern Europeans and probably
occurred in a single individual about 6000 years ago (Cox et al 1985). The prevalence
of this mutant gene is relatively high suggesting that at least those with the
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heterozygous genotype, if not the homozygous recessive as well, must have had some
positive selection advantage over the normal genotype (Kueppers, 1972). Estimates
put the prevalence of the MZ phenotype to be around 5% in Scandinavians, 1.5% in
Britons, 1-2% of Southern Europeans and about 2.2% in the heterogeneous white
population of the United States ofAmerica (Carrell and Owen, 1979).
The Z mutation is caused by a single base substitution (Glu342—>Lys) resulting in the
loss of a conserved negatively charged glutamic acid residue for a positively charged
lysine which is thought to disrupt an ionic bond implicated in the stabilisation of the
molecule (Loebermann et al 1984; Massi, 1996). There appears to be normal
production of the protein in the hepatocyte and about 15% is successfully secreted
into the plasma. The remaining 85% of the API becomes blocked in the rough
endoplasmic reticulum of the hepatocytes prior to the final processing of the
carbohydrate sidechains and so probably does not enter the Golgi complex (Hercz et
al 1978; Hercz and Harpaz, 1980). This accumulation of protein in the hepatocytes is
clearly visible on histological sections as perioic-acid-Schiff positive, diastase-resistant
globules (Clausen et al 1984). Along with the reduced plasma concentration ofAPI in
the ZZ phenotype (Brantly et al 1991) there is also reduced ability to interact with and
inhibit HNE (Ogushi et al 1987; Padrines et al 1989). The delay time of inhibition is
the time required for almost complete inhibition of a proteinase in vivo and is a
measure of whether an inhibitor will play an efficient proteolysis preventing function,
values of less than 1 second are required to prevent uncontrolled HNE activity
(Crystal, 1996). This value can be calculated for different phenotypes of API and also
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different states of the molecule i.e. native or oxidised. The ZZ phenotype has a greater
delay time of inhibition (Table 1.4) (Padrines et al 1989; Brantly et al 1991) which
probably results in a reduced anti-elastase screen and a greater chance ofNE induced
pathology.
API Serum PELF3 Association Delay time of
Phenotype Concentration Concentration constant kass inhibition
(fiM) (pM) (M-'s1) (sec)
M1M1 20-53 4.6 9.6 X 106 0.12
ZZ 3.4-7.0 0.46 4.6 X 106 2.40
SS 20-48 1.2 7.1 X 106 0.60
Oxidised MlMl 20-53 4.6 7.0 X 103 155.00
Table 1.4 - Comparison of concentrations and the kinetics of inhibition in different
API phenotypes. a pulmonary epithelial lining fluid.
The second most common deficiency phenotype, the homozygous S allele is also a
single base mutation Glu264—»Val, again this disrupts a stabilising ionic bond within
the molecule (Elliott et al 1996b). The loss of stability is even greater here and
probably contributes to most of the nascent protein being degraded with no
intracytoplasmic inclusions or pathology seen on histological examination of the liver
(Carrell and Owen, 1979; Loebermann et al 1984). The SS phenotype has a plasma
API concentration of 20-48pM (Brantly et al 1991). The critical level of plasma API
concentration below which the lungs appear to be susceptible to excessive NE activity
is about 1 lpM (Wewers et al 1987; Brantly et al 1991). If either the Z or S allele are
combined with an M allele their respective plasma API levels are 15-42pM and 18-
52pM and so pulmonary diseases are less likely. However, in the SZ phenotype the
plasma levels vary from 10-23pM and about 10% of these individuals develop
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premature emphysema (Brantly et al 1991). In both forms, ZZ and SZ, clinical signs
ofpremature emphysema typically begin in the third to forth decade of life (Brantly et
al 1988; Cox, 1989) the average age of onset being about 10 years sooner if the
subject is a cigarette smoker. The latter case is probably due to oxidative inactivation
ofAPI directly by inhaled oxidants and indirectly from the oxidative radicals liberated
from activated neutrophils which are attracted by chemotaxins released by alveolar
macrophages in response to cigarette smoke (Carrell and Owen, 1979; Janus et al
1985; Gadek and Pacht, 1996a).
The ZZ phenotype results in clinically apparent liver disease in about 10% ofjuveniles
(cholestatic hepatitis) and is also diagnosed in a number adults. The mutation induced
structural instability in the ZZ phenotype results in the noncovalent insertion of the
reactive site loop of one molecule into the A sheet of another, producing a dimer. This
is followed by a cascade of events leading ultimately to polymerisation of ZZ API in
the rough endoplasmic reticulum and precipitation (Lomas, 1994). These precipitates
are seen as globular inclusions under light microscopy and are responsible for the 85%
of ZZ API that is synthesised but not secreted. It is thought that even though these
globules are unlikely to be directly toxic their presence disrupts the normal frmctions
of hepatocytes and renders them more prone to external insults. As only a small
number of infants are clinically affected investigators have looked for some
predisposing factor or triggering device. It is now thought that the hepatitis C virus
and other as yet unidentified viruses are responsible for this (reviewed in Massi,
1996).
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Alpha-1-proteinase inhibitor deficiency has also been associated with a rare form of
relapsing panniculitis, its role in the pathogenesis still remains obscure but as the initial
pathological change is splaying of collagen bundles by neutrophils the link with
potential elastase activity is apparent (Oriordan et al 1997).
1.8 Equine Alpha-l-Proteinase Inhibitor
1.8.1 Historical Context
The initial interest in equine API stemmed from the potential role of the horse as a
disease model as it was considered the only animal besides man to suffer from
spontaneous pulmonary emphysema (Gillespie and Tyler, 1969; Gerber, 1973). The
interest was heightened when it was found that horses mainly developed pulmonary
emphysema in neutrophil associated lung diseases such as chronic obstructive
pulmonary disease (COPD) (Kaup et al 1990; Robinson et al 1996). However, to
date, no deficiency of API has been reported in the horse so there is no true analogy
with human API deficiency.
1.8.2 Genetics, Structure and Function
Unlike human API which is transcribed from a single gene producing one plasma
glycoprotein (Crystal, 1989), equine API consists of four or five plasma glycoproteins
controlled by four closely linked loci named serine proteinase inhibitor (Spi) 1, 2, 3
and 4. Limited sequence data suggests that these four loci are all derived from the
identical ancestral gene that gave rise to human API (Patterson and Bell, 1989;
Patterson et al 1991). Peptide and immunopeptide mapping confirms the close
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relationship between the four loci but also reveals that Spil and 2 are more closely
related to each other as are Spi3 and 4 indicating that these two pairs probably
diverged from two closely related genes (Patterson et al 1991). To date 22 equine
API haplotypes have been isolated, two of these being confined purely to Equus
przewalskii (Putt and Whitehouse, 1983; Patterson et al 1991). Of the remaining 20
found in E. callabus eight are common in the Thoroughbred; F, G, I, L, N, S, T (also
known as S2) and U (Pollitt and Bell, 1983a; Pollitt and Bell, 1983b). The Spi4 gene
is only expressed in 5 of the 22 haplotypes; F, J, T, V and Z (Patterson et al 1991).
The Pi system is considered to be the most complex protein system in the horse and
its inheritance has been used for study of the phylogenetic relationships of the equidae
(Putt and Whitehouse, 1983) and for parentage verification (Bell et al 1984).
Equine APIs are glycoproteins with asparagine linked bi-antennary CHO side chains
present on all of the Spi proteins (Patterson and Bell, 1990). The Spi 3 protein
consists of two isoforms, A and B, which differ in molecular weight and acidity but
have identical N-terminal amino acid sequences (Patterson et al 1991). The difference
in molecular weight and acidity partially correlates with that of two extra terminal
sialic acid residues on a CHO side chains of the most acidic Spi3 (Patterson and Bell,
1986; Patterson and Bell, 1990). The N-terminal amino acid sequences of the Spi
proteins were initially investigated by two groups, one suggested that they are all
identical over the first 32 residues (Potempa et al 1991b) while the other found
significant differences in each Spi protein examined (Patterson et al 1991). A more
recent study in this laboratory agrees with the latter (Pemberton el al 1993).
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All of the Spi proteins inhibit ENE 2A, 2B and other proteinases but have differing
rates of association and inhibition (Potempa et al 1991b) (Pemberton, A.D., personal
communication). One interesting species difference between human and equine API is
that in the horse complexes of API and ENE do not stimulate chemotaxis of equine
neutrophils suggesting that the complex is not involved in the migration of equine
neutrophils to sites of inflammation (Scudamore et al 1993). Biochemical and other
differences may be due to variations in their respective structures (Table 1.5).
Criterion
LOCUS
Spil Spi2 Spi3 Spi4
Isoelectric point 4.02-4.43 4.18-4.35 3.73-4.08 (A) 4.12-4.27
3.92-4.26 (B)
Relative mass Mr 58000 61000 66000(A) 59700
62200(B)
Inhibitory activity Trypsin/ Chymotrypsin Trypsin Trypsin
chymotrypsin
Oxidation Yes No No No
sensitivity
Pi residue Methionine Isoleucine Alanine Arginine
Terminal sialic 4/5 4/5 8(A)/6(B) 4/5
acid content
CHO side chain Biantennary Biantennary Bi- and Biantennary
structure Triantennary
Average plasma
concentration: 1 -4g/l 0.4g/l 1 -6g/l 0.8g/l
Association rate
constant with :
ENE2A (M"V) 2.81 x 107 1.69 x 107 2.25 x 105 ND
ENE 2B (M"'s"') 5.0 x 107 ND 5.2 x 105 ND
Table 1.5 - Summary of biochemical data for the Spi proteins of equine API.
ND = not determined. Pooled data from (Patterson et al 1991) (Potempa et al 1991b)
and (Pemberton, A.D., unpublished data)
Spil with a P| of methionine, an average concentration of 1.4g/l, inhibitory activities
against trypsin and chymotrypsin plus an association rate constant of 107 with ENE
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2A and 2B is the functional equivalent of human API. Oxidation of the Pi methionine
to methionine sulphoxide reduces the association rate constant with ENE dramatically
(from 107 to 0) (Potempa et al 1991b) again analogous to the human situation (Table
1.7). Biochemical, functional and structural studies of Spil from three different
haplotypes, I, L and U, concluded that even though haplotype U has a larger
molecular weight (Mr 57800) than I and L (Mr 55600) all had identical N-terminal
amino acid sequences and association rate constants with ENE 2A (Pemberton et al
1993). The plasma concentration of Spil is the most consistent between haplotypes as
determined by video densitometry, with Spi2 also having comparable plasma
concentrations. However, the concentration of Spi3 varies between haplotypes by up
to 50% (Patterson et al 1991). Both isoforms of Spi3 have been shown to be
oxidation resistant (Patterson and Bell, 1989) due to the Pi residue being alanine, not
methionine (Potempa et al 1991b). This suggests that Spi2 and Spi4 would also be
oxidation resistant as neither of them possess an oxidation sensitive Pi residue
(isoleucine and argenine respectively, Table 1.5).
From the biochemical and limited N-terminal amino acid data available and due to the
conserved nature of the serpins, it is considered that analogies on the general structure
of equine API can be derived from the more extensively investigated human API.
1.8.3 Equine Alpha-1-Proteinase Inhibitor and Disease
No deficiency of equine API has ever been recorded despite over 5500 samples being
examined by one group alone (Pollitt and Bell, 1983b) and this is consistent with
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experience in our own laboratory. Investigations into disease associations with equine
API have fallen into two main categories, reproductive disorders such as endo- and
pyometritis and pulmonary disease, especially COPD. The common factor linking
these diseases is the prominent role of the neutrophil in the inflammatory process
(Haslett et al 1989; Bokoch, 1995; Downey et al 1995).
Endo- and pyometritis is characterised by intense neutrophilic infiltration of the
endometrium (Watson, 1988). Studies in Thoroughbred mares with pyometritis have
shown the frequency of the N haplotype, which is already high in the Thoroughbred
population, was significantly increased compared to that of a large published
population. Also, in mares with acute endometritis that persisted after treatment and
sexual rest, the absence of both the S and T haplotypes was significant, suggesting
that when present they may have a protective role (Pemberton et al 1994). The exact
mechanism of this protected role has not yet been elucidated. Another study assessed
the level of equine API in uterine flushings before and after experimentally induced
endometritis in anoestrus, oestrus and dioestrus. Significant increases in both equine
API and albumin compared to total protein were found in flushings of diseased mares
during oestrus and dioestrus but not anoestrus. A positive correlation between the
concentrations of API and albumin in the flushings led to the conclusion that the API
present had diffused from the plasma rather than being locally synthesised (Scudamore
et al 1994).
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After lameness, respiratory disease is the commonest disorder resulting in wastage in
the horse. In older animals (> 7 years) the most prevalent respiratory disease is COPD
(Winder, 1987) which a Swiss study found histological evidence for in 37% of
necropsied horses from a veterinary teaching hospital over a one year period (Winder
and Von Fellenberg, 1987). Aetiologically COPD is considered to be the result of a
late phase hypersensitivity response to inhaled antigens particularly the thermophilic
moulds and actinomycetes that grow on poorly conserved hay and straw. As a result
of this COPD is mainly found in temperate climates where horses are stabled for long
periods, bedded on straw and fed hay (Robinson et al 1996). Diagnostically it is
characterised by an increase in percentage and absolute number of neutrophils in
broncho-alveolar lavage fluid (BALF) (Freeman et al 1993; Dixon et al 1995a).
Horses with COPD can be induced into remission by environmental management,
involving increasing ventilation and using bedding and feed that are free from
sensitising antigens and allergens (Robinson et al 1996). During remission, the
number of neutrophils found in BALF returns to that of unaffected horses (Dixon et
al 1995b).
All studies of equine API with respect to lung disease have been confined to
investigations ofCOPD. The concentrations of equine API and albumin in PELF from
horses with active clinical signs of COPD were significantly higher than those of
COPD positive horses in remission. The correlation between API and albumin in the
PELF suggested that most of the API was derived from plasma (Milne et al 1994c) in
agreement with studies on equine endometritis (Scudamore et al 1994). Further
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studies uncovered a significantly lower proportion of Spi3B and a higher proportion
of Spil in broncho alveolar lavage fluid (BALF) compared with serum in both control
and COPD affected horses (Milne et al 1994a). This has been interpreted as a
physiological phenomenon possibly due to proteolytic damage or preferential complex
formation by Spi3. Equine APIs in BALF have also been shown to have a lower
molecular weight than that of serum (1.5kDa) in control, symptomatic and
asymptomatic COPD positive horses (Milne et al 1994b). This was initially proposed
to be physiological as lack of evidence of bacterial contamination in the samples
suggested that cleavage by bacterial proteinases was unlikely. However, more recent
data suggests this may have been due to changes in the APIs induced by the method
of concentration of the BALF prior to being subjected to 10% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). If the BALF concentration
equipment used by Milne et al, 1994 (Microsep® concentrators, Filtron Technology
Co., Northborough or Nanosep® concentrators, Intersep Filtration Systems,
Wokingham, Berks., UK) which requires centrifugation is replaced by a method that
does not require centrifiigation (Nanosep™ N10 concentrators, Intersep Filtration
Systems, Wokingham, Berks., UK) then the 1.5kDa molecular weight shift seen on
10% SDS-PAGE does not occur (Preliminary studies, M. P. Dagleish).
1.9 Comparison of Human and Equine Susceptibility to Emphysema
Ultrastructural studies in horses with COPD show focal changes in the alveolar region
including necrosis of type I epithelial cells, variable alveolar fibrosis with type II
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epithelial transformation and emphysema or hyperinflation with an increase in number
of Kohn's pores. The alveolar changes are mostly in the peribronchiolar region and
emphysema was common in areas with bronchiolar obstruction (Kaup et al 1990). In
humans emphysema is mainly centrilobular in distribution with neutrophil associated
pulmonary disorders or panacinar with genetic API deficiency (Snider, 1992; Tetley,
1993; Travis et al 1994). Pulmonary emphysema has been shown to be due to an
imbalance in proteinase:antiproteinase activity in humans (Laurell and Eriksson,
1963), and experimentally in dogs (Janoff et al 1977; Janoff et al 1979), hamsters
(Hayes et al 1975) and mice (Starcher and Williams, 1989). The different patterns in
the horse and human may therefore be due to species differences in total synthesis of
both neutrophil elastase and API or to different concentration or functional activities
and interactions of the two molecules.
Horses appear to develop pulmonary emphysema in neutrophil associated disorders
such as COPD with a severity of histological changes comparable to the degree and
extent of clinical findings (Kaup et al 1990). However, even in the most severe cases
of equine COPD the extent of tissue damage and pulmonary emphysema is much less
than that found in human chronic obstructive airway diseases (Creagh and Krausz,
1992). This suggests that the equine lung is more protected from damage induced by
the host neutrophils which might due to a more favourable anti-proteinase quota in
the proteinaseranti-proteinase equilibrium. This could arise from two potential
mechanisms 1) a lower level of elastase in equine neutrophils (Dubin and Koj, 1986)
or reduced release ofmediator resulting in a reduced amount of local proteolysis in an
45
inflammatory situation, or 2) increased local equine API producing a more efficient
anti-elastase screen in the lower respiratory tract of horses, or a combination of the
two.
It is assumed that plasma equine API is mainly derived from hepatic synthesis as has
been shown in humans (Alper et al 1980; Hafeez et al 1992), there is no direct
experimental evidence to substantiate this but API has been localised in equine liver
tissue by immunohistochemical means (Winder et al 1989). However, it has been
shown that API present in the PELF of horses is probably derived from plasma API
(Milne et al 1994c). This suggests that a greater concentration of plasma API would
result in a greater concentration of API in PELF hence a more effective anti-elastase
screen. The discovery of the synthesis and release of API from many extrahepatic
human tissues suggests that the horse may also have API synthesising extrahepatic
cells which could contribute significant amounts of protein locally for example in the
alveoli.
Equine neutrophils are believed to contain much less NE (Dubin et al 1976) than
human neutrophils (Campbell et al 1989) and this has been proposed as a possible
reason for different patterns of pulmonary emphysema in the two species. However,
the amount of ENE in equine neutrophils was derived by evaluation of elastinolytic
activity of neutrophil extracts, whereas the human figure was derived by
immunological means independent of the activity of NE. The discovery of horse
leukocyte elastase inhibitor (HLEI), an intracellular NE inhibitor within the cytosol of
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equine neutrophils (Potempa et al 1988; Kordula et al 1993) along with evidence that
human neutrophils have been shown to express the API gene and produce API
(duBois et al 1991), brings the accepted figure of NE in an equine neutrophil in to
question as some may be inhibited during the extraction process and so not be
available for detection by means of its activity.
In addition equine neutrophils have been shown to differ in release and generation
characteristics from human neutrophils in their response to identical secretagogues
(Brazil et al 1998). If the kinetics of release ofNE and synergistic products such as
superoxide anions (SOA) (Ottonello et al 1992; Ras et al 1992) differ, in that
significantly lower amounts are released or over a longer time scale, their effects
might be more easily inhibited and this could contribute to an altered
proteinase:antiproteinase balance.
1.10 Aims of this Study
The aims of this study are to evaluate aspects of the equine proteinase:antiproteinase
equilibrium, in an attempt to better understand the reason for the differences in
patterns of pulmonary emphysema between man and horse. Specific antibodies for
equine API and equine neutrophil elastase were developed. These antibodies were
used to:
i) evaluate equine tissues and peripheral blood leukocytes for the possibility
of significant local production of extrahepatic API.
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ii) re-examine the accepted theory that equine peripheral blood neutrophils
are relatively deficient in NE compared to human neutrophils by a
method independent ofNE activity.
iii) examine the kinetics of release ofENE 2A from Percoll purified
equine peripheral blood neutrophils stimulated with a secretagogue




2.1 Reagents and Solutions
All reagents were from Sigma Chemical Co. Ltd., Dorset, UK unless otherwise stated.
Phosphate buffered saline (PBS) was prepared as described in Appendix 1.
2.2 Experimental Animals
2.2.1 Mice
Female balb/c mice were obtained from Bantam and Kingman Universal, Hull, UK,
fed a standard pelleted diet and given water ad libitum. For monoclonal antibody
production mice were deeply anaesthetised in an induction chamber with halothane
(Rhone Merieux, Dublin, Ireland) prior to antigen inoculation. Mice were, similarly,
deeply anaesthetised and killed by sectioning of the brachial artery and exsanguination
and cervical dislocation, the spleen was then collected aseptically.
2.2.2 Sheep
One year old Suffolk cross sheep (from the Moredun Research Institute, Edinburgh,
UK), were fed hay plus a standard sheep concentrate (16% protein) at 0.25Kg/ sheep
per day and given water ad libitum. All pre-mortem blood sampling was by jugular
venipuncture. Sheep were killed by jugular infusion of pentobarbitone sodium B.P.
Vet (Rhone Merieux, Dublin, Ireland) followed by sectioning of the carotid artery and
jugular vein to allow collection ofblood for serum harvesting.
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2.2.3 Horses
Horses were from the Royal (Dick) School of Veterinary Studies research herd, 2
geldings, 4 mares with ages ranging from 8 to 29 years, mean 15.8 years. All were
housed in single stables, bedded on soft wood shavings, fed haylage or big bale silage
(supplied by various local proprietors) and given water ad libitum. Blood sampling
was by jugular venipuncture.
2.3 Sampling and Storage of Serum
Sera from all species was harvested by allowing blood to clot at 37°C for 30-60
minutes. The clot was then separated from the sides of the collection vessel, cut into
several smaller fragments and stored at 4°C overnight to allow the clot to contract.
Serum was harvested, aliquoted (mice 50pl, sheep and horses l-50ml) and stored at -
20°C until required. Equine serum, as a source of API, was obtained from horses
presented for post-mortem examination, collection of blood was within 20 minutes of
death after euthanasia by jugular infusion of Somulose (Arnolds Veterinary Products,
Shrewsbury, UK) followed by sectioning of the carotid artery and jugular vein
exsanguination. Equine plasma was collected into vessels containing 100ml sterile
1.36% ethylenediaminetetraacetic acid (EDTA) per litre of blood, the plasma being
removed after free sedimentation of erythrocytes. Remaining erythrocytes were
removed by centrifugation 1000 x g (Heraeus Megafuge 1.0R, Heraeus Equipment
Ltd., Essex, UK), plasma was stored (l-50ml) at -20°C until required.
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2.4 Determination of Purified Protein Concentration
2.4.1 Bicinchonic Protein Assay
The microtiter plate protocol recommended by the manufacturer (BCA Protein Assay
Reagent, Pierce, Rockford, Illinois, US) was followed to determine protein
concentrations. Absorbance of samples and standard curves was read at 570nm on a
MR7000 ELISA plate reader (Dynex Technologies, Billingshurst, West Sussex, UK).
The standard curve (bovine serum albumin (BSA) range of 15.6-2000pg/ml) and
unknown samples were prepared in triplicate. Microsoft Excel 5.0a software was
utilised to derive sample protein concentrations from the standard curve.
2.4.2 Ultra- Violet Spectrophotometry
Protein concentration was also determined by measuring the absorbance of a solution
at wavelengths of 280nm and 260nm using a Beckman spectrophotometer DU 650
(Beckman Instruments, Inc., CA, US). The absorbance values were used in the
following equation to determine protein concentration:
Protein concentration = (1.55 x A280nm) - (0.77 x A26onm) mg/ml.
2.5 Electrophoresis
All gels were cast and run using the Bio-Rad Mini-Protean II system (Bio-Rad
Laboratories Ltd., Hertfordshire, UK). Gels and running conditions were based on
modifications of previously published methods (Paakko et al 1990) (Krugliak et al
1986).
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2.5.1 Sodium Dodecylsulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Buffers and chemicals:
1. Acrylamide- 30% acrylamide/ 0.8% bis-acrylamide
2. Resolving buffer- 1M Tris-HCl titrated to pH 8.8
3. Stacking buffer- 0.5M Tris-HCl titrated to pH 6.8
4. Sodium dodecylsulphate (SDS)- 10% w/v in dH20
5. Ammonium persulphate (APS)- 10% w/v in dH20 (made fresh daily)
6. N,N,N',N'-Tetramethylethylenediamine (Temed)
7. Tank buffer- 0.3% Tris, 1.44% glycine, 0.1% SDS pH 8.3




Bromophenol blue (0.1% w/v) 0.5ml
The solutions were mixed according to the table below to give gels with the required
resolution.
Solution Stacking Gel Resolving Gel Resolving Gel
(4%) (10%) (12%)
Resolving buffer (ml) - 2.5 2.5
Stacking buffer (ml) 1.4 - -
Acrylamide (ml) 0.72 3.35 4.1
Water (ml) 2.95 3.05 2.3
SDS (ml) 0.28 1.0 1.0
Temed (pi) 10 10 10
APS (pi) 100 100 100
Table 2.1 - Composition of ingredients for different SDS gels for PAGE.
Samples in reducing buffer were heated to 100°C for 3 minutes before loading onto
gels. Gels were run at 200V for approximately 45 minutes, electrophoresis was




1. Acrylamide- 30% acrylamide/ 0.8% bis-acrylamide.
2. Gel buffer- 1,5M Tris (25ml)
2-Mercaptoethanol (75pi)
Temed (0.5ml)
dH20 was added to a volume of 70ml then titrated to pH 7.8 with
20% H2S04 and made up to 100ml total volume.
3. Ammonium persulphate- 0.2% w/v in dH20.
4. Blue dextran solution- 1% w/v in dH20.
5. Tank buffer- 65mM Tris-borate, pH 9.0.
7.87g Tris
lg Boric acid -made up to 1L with dH20
Solution Stacking Gel Resolving Gel (11.2%)
Acrylamide (ml) 0.5 4.48
Gel buffer (ml) 1.0 3.0
Ammonium persulphate (ml) 1.0 3.0
Blue dextran solution (ml) 1.5 -
dH20 (ml) - 1.52
Temed (pi) 2.0 -
Table 2.2 - Composition of ingredients for 11.2% native gel.
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Non-reducing sample buffer was made by substituting dH20 for 2-mercaptoethanol in
the reducing buffer described above. Gels were run at 250V for approximately 50
minutes, electrophoresis was stopped when the bromophenol blue dye front was
within 2mm of the bottom of the gel.
2.6 Visualisation of Electrophoresed Proteins
2.6.1 Coomassie Brilliant Blue
Fixation and staining of protein on polyacrylamide gels was with 0.25% w/v
Coomassie brilliant blue (R-250) dissolved in 45% methanol/ 10% glacial acetic acid
in dH20 for 15 minutes. Gels were destained with 17% methanol/ 5% glacial acetic
acid in dH20 until all background pigment was removed allowing clear visualisation
ofprotein bands.
2.6.2 Short Silver Stain
Gels were fixed with 50% methanol/ 10% glacial acetic acid in dH20 for 15 minutes,
washed in 5% methanol/ 7% glacial acetic acid in dH20 for 10 minutes (twice),
followed by two 5 minute washes in dH20. Dithiothreitol solution (0.5mg in 100ml
dH20) was added for 15 minutes to reduce the proteins followed by three 5 minute
washes in dH20. Gels were incubated in 0.1% silver nitrate in dFI20 for 20 minutes,
rinsed in dH20 for 30 seconds and developed in a solution of 50pl of 40%
formaldehyde in 100ml of 3% Na2C03. Band development was assessed by direct
visualisation of the gel over a light box and inhibited by addition of citric acid
(monohydrate) until the effervescence stopped.
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2.6.3 Trypsin Inhibitor Gels
To identify the trypsin inhibitory properties ofAPI and to identify Spi isoforms (1, 3A
and 3B) samples were first separated by 11.2% native-PAGE. Gels were then
incubated with chymotrypsin free bovine pancreatic trypsin (70pg/ml in 50mM
phosphate buffer, pH 7.4) for 30 minutes at 37°C followed by exposure to a mixture
of N-acetyl phenylalanine-(3-naphthyl ester (APNE, 5mg in 2ml of
dimethylformamide) and Fast Blue salt (lOmg in 18ml of 50mM phosphate buffer, pH
7.4). On development, proteins with trypsin inhibitory properties are seen as clear
bands against a red background as the trypsin is inhibited from cleaving APNE, one of
the products ofwhich reacts with fast blue to form the red colouration. Once staining
is complete gels were washed 3-4 times in dH20 then placed in 2% acetic acid to
inhibit further development.
2.6.4 Substrate Gels to Assess Proteolysis
Proteins were separated by 10% SDS-PAGE under non-reducing conditions with
0.2% azocasein incorporated into the resolving gel (Horie et al 1984). Following
electrophoresis gels were washed 3 times in 2.5% Triton-X 100 for 30 minutes before
overnight incubation in PBS. The resultant gels were stained with Coomassie brilliant
blue solution and destained as described above; proteolysis of azocasein in the gels
being seen as clear bands against a blue background.
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2.7 Western Blotting
Proteins were transferred to polyvinylenedifluoride membrane (Immobilon-P) after
native-PAGE or SDS-PAGE using a semi-dry blotting technique and a triple buffer
method (Kyhse-Anderson, 1984):
Anode Buffer 1- pH 10.4, 0.3M Tris in 20% (v/v) methanol.
Anode Buffer 2- pH 10.4, 25mM Tris in 20% (v/v) methanol.
Cathode Buffer- pH 9.4, 25mM Tris, 40mM 6-amino-n-hexonic acid in
20% (v/v) methanol.
Chromatography paper (3mm thick, Whatman International Ltd., Kent, UK) was cut
to generously accommodate the area of the gel. Two sheets were soaked in anode
buffer 1 and placed directly onto the graphite anode. One sheet soaked in anode
buffer 2 was then placed on top of the other two followed by the inert membrane. The
gel was trimmed and placed carefully over the membrane followed by three sheets of
chromatography paper soaked in cathode buffer with the cathode plate being placed
on top. Protein transfer was complete in 1 hour using a current of 0.8mA/cm2 of gel
(80mA/minigel). The membrane was air dried and stored between filter paper at 4°C
until required.
2.8 Preparation of Affinity Columns
CNBr-activated Sepharose® 4B was soaked and washed several times in 0.1M HC1
being degassed between each wash. On final degassing and draining away of
supernatant the gel was allowed to cake and then added to a solution of affinity
purified sheep anti-equine API antibody (15mg, see Chapter 3.2.1), purified equine
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API (3.5mg, see Chapter 3.2.1) or ENE 2A (lmg, see Chapter 5.2.1) in 0.1M sodium
carbonate buffer/0.5M NaCl, pH 8.3. The mixture was agitated in a universal
container overnight at room temperature. Sodium azide was added (to 0.05%), the
gel packed under gravity into a C-10/10 column (Pharmacia, Uppsala, Sweden) and
stored at 4°C until required.
2.9 Purification of Spil and 3 from Affinity Purified Equine API
Ion exchange chromatography separates biomolecules based on differences in charge
characteristics (cationic/anionic), and is dependent on buffer pH and the isoelectric
point of the biomolecules.
Buffer A: lOOmM NalEPCE (most acidic buffer)
Buffer B: 1 OOmM Na2H2P04 (most basic buffer)
Buffer C: lMNaCl
Buffer D: deionised water
A sample of affinity purified API (see Chapter 3.2.1) was diluted 1:1 with buffer (15%
A, 5% B, 80% D) and loaded on to the Mono Q (strong anion) column. The buffer
composition was then altered over time as shown in Table 2.3 with a constant flow
rate (1ml/minute).
Time (min) A (%) B (%) C (%) D (%)
0.0 15.0 5.0 0.0 80.0
4.0 15.0 5.0 0.0 80.0
44.0 15.0 5.0 40.0 40.0
45.0 15.0 5.0 80.0 0.0
47.0 15.0 5.0 80.0 0.0
48.0 15.0 5.0 0.0 80.0
55.0 15.0 5.0 0.0 80.0
Table 2.3 - Changes in buffer composition with time in Mono Q column.
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Protein content of eluants was monitored by absorbance at a wavelength of 280nm
with 0.5ml aliquots collected during protein elution. Several runs of each haplotype of
API were performed and each fraction was subjected to 11.2% native PAGE to assess
identity and purity of the products. Pure preparations of Spil and 3 for each
haplotype were pooled and the protein concentration determined by the Bicinchonic
Protein Assay method (see above) and stored at -70°C until required.
2.10 Deglycosylation of Purified Spi Proteins
40pi of 1.2% SDS was added to a lOOpl sample of purified Spi protein and placed in
a boiling water bath for 15 minutes. On cooling 200pl of deglycosylation buffer
(Appendix 1) was added along with 35pl (7 IU) of peptide N-glycosidase F (PNGase
F) and incubated at 37°C overnight.
2.11 Purification of Mouse IgGi Antibodies
The NaCl concentration ofmaximum tissue culture supernatant was adjusted to 3.3M
by addition of NaCl (9.64g/50ml) followed by addition of 1.0M sodium borate (pH
8.9) to 1/10 the volume of the supernatant/NaCl mixture. The resultant solution was
passed through a Protein A column (Pharmacia, Uppsala, Sweden), 50ml was loaded
per run, followed by 10 column volumes of 3.0M NaCl, 50mM sodium borate (pH
8.9) and 10 column volumes of 3.0M NaCl, lOmM sodium borate respectively. The
bound antibody was eluted with lOOmM glycine (pH 3.0). Antibody solutions were
immediately neutralised by addition of 1M Tris, pH 10. Antibody solutions from
several runs were pooled, desalted on a Sephadex G25 column (Pharmacia, Uppsala,
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Sweden) into PBS+0.05% sodium azide and concentrated using an ultrafiltration cell
(Amicon Ltd., Gloucestershire, UK). After evaluation of protein concentration
(bicinchonic protein assay, see above) the concentration was adjusted to 2mg/ml then
aliquoted and stored at -20°C until required.
2.12 Conjugation of Antibodies
2.12.1 Horse Radish Peroxidase Conjugate
Five milligrams of horse radish peroxidase (HRPO) was resuspended in 1.5ml dH20
and incubated for 30 minutes at room temperature. 0.25ml of 0.1M sodium periodate
was then added to the HRPO followed sequentially by a 20 minute incubation,
addition of 0.25ml of 0.5M ethylene glycol to quench sodium periodate and a further
20 minutes incubation. The resultant mixture was dialysed overnight at 4°C using a
15,000 molecular weight cut off (MWCO) membrane (Fisher Scientific,
Leicestershire, UK) against 1L of 5mM sodium acetate, pH 4.5, changing the solution
once. Concurrently, 5.0mg of the antibody to be conjugated was dialysed overnight at
4°C using a 15,000 MWCO against 1L of 50mM NaHCOs, pH 8.0 changing the
solution once. To the dialysed antibody solution 4.0ml of 0.4M NaHCOs, pH 10.5
was added followed by addition of the activated dialysed HRPO. The mixture was
then incubated for 2 hours at room temperature. Sodium borohydride (0.50ml, 0.1M)
was added and the reaction mixture incubated for a further 6 hours at 4°C. To
separate the conjugated antibody from the unreacted HRPO the mixture was
concentrated to 2ml and applied to a Supadex 100 column (Pharmacia, Uppsala,
Sweden) equilibrated with PBS. The protein fraction was identified by absorbance of
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light at 280nm, collected and pooled. Protein concentration and protein to enzyme
ratios (RZ) were determined by UV spectrophotometry.
RZ = OD 403nm/ OD 280nm
All HRPO conjugated antibodies were diluted 1:1 with glycerol as a cryoprotectant
and stored at -20°C until required.
2.12.2 Fluorescent Antibody Conjugates
Affinity purified sheep antibodies and normal sheep IgG were conjugated to
fluorescein isothiocyanate (FITC) and Cyanine3 (Cy3) using the FluoroTag1M FITC
T\yf ti i
Conjugation Kit and FluoroLink-Ab Cy3 Labelling Kit (Amersham Life Science,
Inc., Arlington Heights, IL, US) respectively. In both cases the manufacturers'
instructions were followed. Briefly, for sheep anti-ENE 2A antibody conjugation to
Cy3, lmg of antibody in 1ml of PBS was added to coupling buffer (1M sodium
carbonate buffer, pH 9.3) and thoroughly mixed by vortexing. To this, Cy3 dye was
added and thoroughly mixed by vortexing followed by a 30 minute incubation period
during which the mixture was vortexed every 10 minutes. The labelled antibody was
then desalted and separated from the free dye by MW exclusion chromatography on a
gel filtration column (provided in the kit) equilibrated with PBS, 0.1% sodium azide.
Normal sheep IgG was labelled in an identical manner for use as a negative control.
Sheep anti-equine API antibody conjugation to FITC was performed by reconstitution
of the latter in 0.1M carbonate-bicarbonate buffer, pH 9.0 to give a ratio ofFITCTgG
molecules of 10:1 respectively. The FITC was added dropwise while stirring to 4mg
of sheep anti-equine API antibody in the same buffer and incubated for 6 hours at
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room temperature in a light proof container with constant gentle agitation. The FITC
labelled antibody was separated from the unreacted FITC by MW exclusion
chromatography on a Sephadex G-25M column equilibrated with PBS, 0.05% sodium
azide. Normal sheep IgG was labelled in an identical manner for use as a negative
control. Final protein concentrations and fluorochrome to protein ratios were derived
using UV spectrophotometry and the following equations:
FITC Molar F/P = 2.77 x A495 / A2g0 - (0.35 x A495)
Cy3 Molar F/P = (1.13 x A552) / [A280 - (0.08 x A552)]
A = absorbance at a given wavelength of light (nm).
All fluorochrome conjugated antibodies were stored in PBS + 0.05% sodium azide in
light proof containers at 4°C until required.
2.13 Cell Culture
Unless stated otherwise all cell culture associated with monoclonal antibody
production was in plastic tissue culture flasks with vented caps (Costar, Cambridge,
MA, US). Cells were cultured at 37°C in an humidified atmosphere of 5% C02 in air.
2.14 Cell Counting and Viability of Purified Neutrophils
Cell were counted by an automated cell counter (System 9000, Serono Baker
Diagnostics, Pennsylvania, US) or in an improved Neubauer haemocytometer (Fisher
Scientific, Leicestershire, UK). Cell viability was assessed based on trypan blue
exclusion (lOpl cells : lOpl dye).
2.15 Cytospin Preparation and Staining
61
To determine the percentage of neutrophils in preparations of isolated cells, 80pi of
purified cells in platelet poor plasma (PPP) were centrifuged onto a glass slide for 3
minutes at 300 rpm (Shandon Cytospin 3, Southern Instruments Ltd., Runcorn, UK).
Slides were air dried, fixed in methanol for 3 minutes and stained with Diff-Quik™
(B. M. Brown Ltd., Reading, Berks, UK). Slides were then washed with dH20 to
remove excess stain and mounted in DPX (BDH, Poole, UK). The percentage of
neutrophils in each preparation was determined by counting 500 cells from randomly
chosen high power (x 1000) fields.
For immunocytochemical evaluation, cells suspended in equine serum free media were
centrifuged as above onto 3-aminopropyltriethoxysilane (TESPA) coated slides and
fixed in freshly prepared 4% paraformaldehyde in PBS for 45 minutes at 45°C,
transferred to 70% ethanol and stored at 4°C until required.
2.18 Statistical Analysis
Statistical analysis of release of superoxide anion, equine neutrophil elastase 2A and
equine alpha-1-proteinase inhibitor from purified peripheral blood neutrophils was
performed using Minitab 11.12 or GraphPad Prism 2.01 statistical software.
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Chapter 3
GENERATION AND CHARACTERISATION OF SPECIFIC
MOUSE MONOCLONAL AND SHEEP POLYCLONAL
ANTIBODIES TO EQUINE ALPHA-1-PROTEINASE INHIBITOR
3.1 Introduction
Equine API has previously been examined biochemically to investigate the possible
susceptibility to endometritis and pyometritis of Thoroughbred mares in relation to
their API haplotype (Pemberton et al 1994). Equine API has also been quantitatively
evaluated in uterine flushings, by immunological means, from mares at various stages
in their reproductive cycle, as well as during experimentally induced endometritis
(Scudamore et al 1994). This study showed statistically significant differences in the
amount of equine API in the different stages of the normal reproductive cycle but
none in the diseased mares. Similarly, equine API has been quantified in the
pulmonary epithelial lining fluid (PELF) from the lungs of horses suffering from active
symptomatic COPD and those in remission induced by environmental control (Milne
et al 1994c). In this case the animals suffering from the active disease had a
statistically significant higher concentration of equine API in their PELF compared to
those in remission. These quantitative studies into physiological and disease situations
used a polyclonal sheep anti-equine API antibody which, although successful in
detecting equine API in a sandwich ELISA and for affinity purification, was not
consistently useful for immunoblotting or immunohistochemistry.
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To enable further investigation of the role of equine API in the normal physiology of
the horse and with respect to the proteinase:anti-proteinase theory of pulmonary
emphysema, an effective means of recognition and measurement is required that is
consistently specific and sensitive in complex biological samples where other
constituents may also be present (e.g. tissue, serum, cell preparations etc.).
Generation of specific antibodies to the protein under investigation is one way of
achieving this as they are able to detect their protein antigen with a specificity that is
readily demonstrable on Western blots. Antibodies can be employed in both
qualitative (Western blots, immunohistochemistry) and quantitative (ELISA)
evaluations of their antigen.
For this reason a new panel of mouse monoclonal and sheep polyclonal antibodies to
equine API were raised and characterised in an attempt to obtain antibodies which
would be useful for studies involving techniques such as Western blots, tissue
immunolocalisation and ELISA.
3.2 Materials and Methods
3.2.1 Production and Evaluation ofSheep Polyclonal Antibody to Equine API
Protein Purification. Equine API was purified from horse serum by affinity
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chromatography on a sheep anti-equine API antibody column (kindly donated by Dr.
Alan Pemberton). The antibody used for purification (15mg) was coupled to CNBr-
activated Sepharose® 4B (5g) as described in Chapter 2.8.
Pooled equine serum was diluted 1:1 with PBS+0.05% sodium azide and loaded onto
the column in 2ml aliquots. After equilibration with PBS+0.05% sodium azide, bound
equine API was eluted with 2ml of 0.1M citric acid/0.5M NaCl/0.05% sodium azide,
pH 2.5 and immediately neutralised by addition of 1M Tris, pH 10. Several runs were
pooled, desalted on a Sephadex G25 (Pharmacia, Uppsala, Sweden) column into
PBS+0.05% sodium azide, concentrated using a stirred ultrafiltration cell containing a
membrane with a 30000 MW cut off (Amicon Ltd., Gloucestershire, UK). The
protein concentration was adjusted to lmg/ml after assessment by the bicinchonic
protein assay method (Chapter 2.4.1). Aliquots were stored at -20°C until required.
Purity was assessed by 11.2% native-PAGE.
Immunisation of Sheep with Affinity Purified Equine API. Sheep antisera were raised
by mixing equal volumes of affinity purified equine API (lOOpg total protein) and
Freund's complete adjuvant into an emulsion by passing it 20-30 times through a 21G
needle. After blood sampling to provide control serum, the protein:adjuvant emulsion
was injected into four separate subcutaneous sites in the sheep. Two subsequent
immunisations over a 6 month period were performed as above except that the
antigen was emulsified in Freund's incomplete adjuvant. A final injection of 100pg of
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equine API in saline was given by the intra-muscular route 3 days before slaughter,
collection and storage ofantiserum (as described in Chapters 2.2.2 and 2.3).
Antibody Purification. Sheep polyclonal antibodies were purified by affinity
chromatography. Equine API (3.5mg) was coupled to lg of CNBr-activated
Sepharose® 4B (Pharmacia, Uppsala, Sweden) and packed to produce an equine API
affinity column for use in chromatography as described in Chapter 2.8.
Sheep anti-equine API antiserum was diluted 1:1 with PBS+0.05% sodium azide to
reduce viscosity and loaded on to the equine API affinity column. After equilibration
with PBS+0.05% sodium azide, bound material was eluted with 2ml of 0.1M citric
acid/0.5M NaCl/0.05% sodium azide, pH 2.5. Antibody solutions were immediately
neutralised by addition of 1M Tris, pH 10 to a final pH of 7.0. Optimal loading of the
column was assessed by performing the above procedure with increasing sample
volumes, starting with 1ml and increasing by 0.5ml each run, until saturation of the
column was observed from the elution. The sample volume immediately previous to
this was then used on all subsequent runs. Antibody solutions were pooled from
several runs and concentrated using an ultrafiltration cell (Amicon Ltd.,
Gloucestershire, UK) before being desalted. Desalting was achieved by equilibrating a
Sephadex G25 column (Pharmacia, Uppsala, Sweden) into PBS+0.05% sodium azide.
The resultant antibody solution, now in PBS+0.05% sodium azide, was diluted to
lmg/ml after protein concentration evaluation (by the bicinchonic protein assay,
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Chapter 2.4.1) and stored either with or without glycerol (1:1 ratio) at -20°C until
required.
3.2.2 Characterisation of the Sheep Anti-Equine APIAntibody
The specificity of the antibody was evaluated by probing Western blots of purified
equine API and native equine API in serum. Affinity purified whole equine API
containing the same mixture of isoforms found in serum (lpg total protein in 5pi of
native sample buffer) and equine serum (diluted 1:20 in native sample buffer, 5pl
loaded) were subjected to native 11.2% PAGE with blue dextran incorporated into
the stacking gel to retard albumin migration (Pemberton and John, 1993). Four
identical gels were produced, one was stained with Coomassie Brilliant Blue R250,
the second evaluated for trypsin inhibitory properties, while proteins from the others
were transferred to a polyvinylidene difluoride membrane (Immobilon-P) by semi-dry
Western blotting (Chapter 2.7) for further evaluation.
Probing ofWestern blots was achieved by initially blocking non-specific binding of the
antibody with 3% dried skimmed milk (J Sainsbury, London, UK) in PBS (3%MPBS)
for 60 minutes. The membrane was then incubated with the affinity purified sheep
anti-equine API antibody, 2.5mg/ml in 3%MPBS (60 minutes) followed by washing 3
times in PBS+0.05% Tween 20 and once in PBS respectively for 5 minutes each. To
localise sheep anti-equine API antibody, donkey anti-sheep IgG: horse radish
peroxidase (HRPO) conjugate (Sigma Chemical Co., A-3415) was applied at a
1/7500 dilution in 3%MPBS for 60 minutes. Following an identical wash procedure as
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before a 3,3'-diaminobenzidine tetrahydrochloride (DAB) peroxidase substrate kit
(Vector Laboratories, Peterborough, UK) was utilised as per manufacturer's
instructions. On appearance of protein bands the membrane was washed in 3-4
changes of dH20, photographed and subsequently dried on filter paper prior to
storage in a light proof container. An identical procedure was performed on the fourth
Western blot except the primary antibody was substituted with 2.5pg/ml of normal
sheep IgG to act as a negative control.
Sera from Thoroughbred (Tb) horses homozygous for the 8 common haplotypes of
API; F, G, I, L, N, S, T and U (kindly provided by M. Scott, Animal Health Trust,
Newmarket, UK) were diluted 1:20 in native buffer and 5pi of the resultant mixtures
were electrophoresed, transferred to Immobilon-P and probed with the polyclonal
sheep anti-equine API antibody as above.
3.2.3 Production and Evaluation ofMouse Monoclonal Antibodies to Equine API
Production ofMouse Monoclonal Antibodies to Equine API. Mice (BALB/c females)
were immunised 4 times with affinity purified equine API (40pg total protein each
immunisation) from the same stock as that used for immunising the sheep for
polyclonal antibody production. The first immunisation was emulsified with Freund's
complete adjuvant (total volume 0.2ml), the second and third with Freund's
incomplete adjuvant, all being given by the subcutaneous route 4 weeks apart. Sera
obtained from tail bleeds were screened for specific antibodies by enzyme linked
immunosorbant assay (ELISA). Microtitre plates were coated with affinity purified
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equine API (50plAvell of lpg/ml solution in 0.1M carbonate/bicarbonate buffer, pH
9.6, Appendix 1) overnight at 4°C. Following six washes with PBS+0.05% Tween2o
(PBST), sera was diluted 1:100 with PBS and 50pl was added per well and incubated
at room temperature (approx. 21°C) for 60 minutes. Wells were then washed 6 times
with PBST as before. Detection of bound primary antibody was by addition of sheep
anti-mouse IgCTHRPO conjugate (Sigma Chemical Co. A-5906) diluted 1:5000 in 4%
normal sheep serum in PBST for 60 minutes followed after washing six times with
PBST by the addition of 50pl per well of 3, 3', 5, 5'-tetramethylbenzidine (TMB,
Dynex Technologies, Billingshurst, West Sussex, UK) substrate. Colour development
was stopped by the addition of 25pil of 0.18M H2S04 and the optical density (OD)
measured at 490nm on a MR7000 ELISA plate reader (Dynex Technologies,
Billingshurst, West Sussex, UK). Sera from mice taken before immunisation (pre-
immune sera) was used as a negative control being substituted for test sera at the
same dilution.
Mice with serum positive for anti-equine API antibodies on ELISA were given a
fourth injection of soluble affinity purified equine API intraperitoneally 72 hours
before harvesting of spleens and sera (Chapter 2.2.1). Splenic cells were separated by
manipulation of splenic tissue between two sterile glass slides and placed in serum free
tissue culture media (Appendix 2) and washed twice by centrifugation at 400 x g for 5
minutes. An identical wash procedure was performed on cells from a mouse myeloma
cell line (NSO cells from BALB/c mice). All tissue culture solutions were prewarmed
to 37°C prior to use. The two populations of cells were combined and 0.5g of
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prewarmed PEG 4000 diluted 1:1 with serum free media was slowly added over 1
minute with continual stirring. A further 1ml of serum free media was added over the
next 1 minute followed by 9.0ml over the next 2 minutes with continuous stirring. The
cells were then centrifuged at 400 x g for 5 minutes (Harlow and Lane, 1988). The
supernatant containing the PEG was removed and RPMI 1640 (Gibco BRL, Life
Technologies Ltd., Paisley, UK) containing 20% foetal calf serum (FCS, Gibco BRL,
Life Technologies Ltd., Paisley, UK) that had been previously screened to assess
suitability for mouse myeloma cell growth (Appendix 2) was added. Following
assessment of cell density (improved Neubauer haemocytometer, Fisher Scientific,
Leicestershire, UK) dilutions of cells were made such that lOOpl contained either 1 or
5 cells. Each lOOp.1 sample was placed in the well of a 96 well plate and incubated in
an humidified incubator at 37°C, 5% C02.
Supernatants from wells containing viable cells after hypoxanthine, aminopterin and
thymidine selection were screened for specific antibodies using the ELISA method
described above. Positive anti-equine API antibody producing cell lines, of which one
(1.3.2) was produced by this study and another (IB) was kindly donated by Dr. Sybil
McAleese were cloned by limiting dilution.
The two cell lines were grown to produce maximum supernatant in static culture; the
point where the maximum amount of antibody is found in the supernatant produced in
a single tissue culture flask. Maximum supernatant was defined by a reduction in cell
growth and viability as monitored by microscopic visualisation and decrease in pH as
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indicated by yellowness of the tissue culture media (due to the presence of pH
sensitive phenol red). Maximum supernatants were decanted and centrifuged at 10000
x g to remove cell debris and stored at -20°C until purification of antibodies.
Characterisation of Mouse Monoclonal Antibodies. A Mouse Monoclonal Antibody
Isotyping Kit established that both monoclonal antibodies (IB and 1.3.2) belonged to
the IgGi isotype. Initial characterisations of the two monoclonal antibodies were
carried out using neat tissue culture supernatants as a source of anti-equine API
antibody. Supernatants were used to probe Western blots made from a 1/20 dilution
in native sample buffer of sera from the 8 common API haplotypes found in
Thoroughbreds (kindly provided by M. Scott of the Animal Health Trust, Newmarket,
UK) subjected to 11.2% native PAGE (described above and see Chapter 2.5.2).
Non-specific antibody binding was blocked with 0.5% Tween80 in PBS (PBST80) for
60 minutes. Neat tissue culture supernatants from mAbs IB and 1.3.2 were added to
separate but identical Western blots for 90 minutes followed by three 5 minute washes
in PBST80. Antibody binding was visualised by addition of goat anti-mouse IgG (Fab
specific):HRPO conjugated antibody (Sigma Chemical Co., A 2304) diluted 1/5000 in
PBST80 for 60 minutes followed by three 5 minute washes in PBST80 and incubated
with DAB HRPO substrate (Vector Laboratories, Inc., Peterborough, UK). Once
protein bands were visualised the membrane was washed in 3-4 changes of dH20,
photographed and subsequently dried on filter paper before storage in a light proof
container. For control purposes mAbs IB and 1.3.2 were substituted with supernatant
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from a mouse cell line producing IgGi raised to rat mast cell proteinase II (kindly
provided by John Huntley, Moredun Research Institute, Edinburgh, UK).
3.2.4 Evaluation of Effects of Glycosylation on Recognition of Spi Isoforms by
Monoclonal Antibodies
In order to further evaluate the specificities of the two monoclonal antibodies the Spil
and 3 isoforms from haplotypes N, S and U were purified, deglycosylated,
electrophoresed and transferred to Immobilon-P by Western blotting. The aim of this
procedure was to compare the two monoclonal antibodies to assess if their difference
in specificity was due to:
i) the antibodies binding to a CHO epitope rather than a peptide one.
ii) the more branching and therefore more bulky CHO side chains of
Spi3 (Patterson and Bell, 1990) obstructing antibody binding to
peptide epitopes close to them.
Purification of Isoforms Spil and 3 ofEquine API. Equine API was purified from the
sera of horses known to be homozygous for haplotypes N, S and U (kindly provided
by M. Scott, Animal Health Trust, Newmarket, UK) by affinity chromatography
(Chapters 3.2.1 and 2.8). Each haplotype of affinity purified API was then subjected
to ion exchange chromatography using HPLC and a Mono Q column (Pharmacia,
Uppsala, Sweden) as described in Chapter 2.9 to purify Spil and 3.
Deglycosylation and Western Blotting of Spil and 3. Previous studies have shown
that equine API contains complex N-linked CHO side chains attached to asparagine
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residues and these bonds are cleaved by peptide N-glycosylase F (PNGase)
(Patterson and Bell, 1990). The purified Spil and 3 from haplotypes N, S and U were
deglycosylated as described in Chapter 2.10.
Glycosylated and deglycosylated samples of identical haplotypes and isoforms
(0.26pg/lane) were subjected to 10% SDS-PAGE under reducing conditions in
adjacent lanes. Three identical gels were produced from the Spil and Spi3 isoforms.
For each isoform one gel was stained by the short silver stain (Chapter 2.6.2),
proteins from the other two were transferred to Immobilon-P by Western blotting
(Chapter 2.7). One blot was probed with mAb IB the other with mAb 1.3.2 as
described above.
3.2.5 Purification ofAnti-Equine APIMonoclonal Antibody IB
As mAb IB recognised the greater number of Spi proteins and in a greater number of
haplotypes it was considered that it would probably be the most useful monoclonal
antibody against equine API for use in further investigations in tissues from untyped
animals. For this reason and to be able to critically control the concentration of
antibody employed in various procedures it was decided to purify mAb IB. A Protein
A hydrophobic interaction chromatography using a high salt, triple buffer technique
was considered the best method for purification of a mouse IgGi antibody (Harlow
and Lane, 1988) as described in Chapter 2.11.
A Western blot of the sera from the 8 common Tb haplotypes ofAPI identical to that
used to characterise the neat tissue culture supernatant (Chapter 3.2.3) was prepared
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and probed in an identical manor except purified mAb IB (40pg/ml in PBST80)
replaced the neat tissue culture supernatant. A duplicate Western blot was probed by
substituting 40pg/ml of normal mouse IgGi (MOPC 31c, Sigma Chemical Co., M
9035) for mAb IB as a negative control.
3.3 Results
3.3.1 Production and Evaluation ofSheep Polyclonal Antibody to Equine API
The affinity purified equine API was not contaminated with other serum proteins
when examined by Coomassie brilliant blue stained native 11.2% PAGE (Figure 3.1).
A combination of Coomassie stained and trypsin inhibitor native PAGE allows
individual identification ofSpil-3 (Milne et al 1994a) (Figure 3.2).
API S
Figure 3.1 - Coomassie brilliant blue (R-250) stained 11.2% native PAGE of affinity
purified equine API and equine serum (S).
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API S
Figure 3.2 - 11.2% native PAGE of affinity purified equine API and equine serum (S)
stained for trypsin inhibitory capacity. Spil (black arrow) migrates the furthest, Spi3A
(green arrow) and Spi3B (red arrow) migrate the least, all are seen as clear bands on
the pink background. Spi2 does not inhibit trypsin and so is not visible. The high MW
band of inhibition corresponds to dimeric API (white arrow). Esterase is seen as a
dark pink band (grey arrow).
Polyclonal sheep anti-equine API antibody specifically recognises Spil, 2 and 3 in the
presence of other serum proteins on a Western blot made from a gel identical to that
in Figure 3.1 (Figure 3.3), dimeric API is also clearly recognised. Due to the presence
of Spi4 in only 5 of the 22 known equine API haplotypes it was not considered further
in these studies. The negative controls were unstained. The Western blot of the sera
from the 8 common Tb haplotypes established that all Spi isoforms of equine API
present were recognised by the polyclonal sheep anti-equine API, with only slight








Figure 3.3 - Western blot made from an identical gel to that ofFigure 3.1 and probed
with sheep polyclonal anti-equine API antibody which specifically recognises all Spi
proteins present and the dimeric form (D) in the presence of other serum proteins (S).









F G I N U
Figure 3.4a - Coomassie brilliant blue (R-250) stained 11.2% native-PAGE of the
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Figure 3.4b - Western blot made from an unstained gel identical to that in Figure 3.4a
probed with sheep anti-equine API. All Spi isoforms were recognised including the
dimeric form (D) with slight variations in the intensity of the positive staining,
however 2-dimentional PAGE is needed to resolve some of these in certain
haplotypes.
3.3.2 Evaluation ofMouse Monoclonal Antibodies to Equine API
Monoclonal antibody IB (mAb IB) specifically recognised all isoforms ofAPI present
in the sera of the 8 common Tb haplotypes but with variation in the intensity of
immunostaining of individual Spi proteins of certain haplotypes (Figure 3.5). The Spi3
isoform of haplotypes N, S and T were less intensely immunostained by mAb IB and
dimeric API was recognised in all haplotypes except G. In contrast, mAb 1.3.2 only
recognised Spil and 2 and then only in haplotypes G, I, L, S, T and U (Figure 3.6).
Spil and 2 of haplotypes F and N and Spi3 of any haplotype were not recognised by
mAb 1.3.2. The negative control preparation was devoid of any labelling.
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Figure 3.5 - Western blot from a gel identical to that in Figure 3.4a probed with mAb
IB. Note variation in intensity of staining of Spi isoforms in different haplotypes and
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Figure 3.6 - Western blot from a gel identical to that in Figure 3.4a probed with mAb
1.3.2 which only recognises Spil and 2 and then not in all haplotypes examined.
Recognition ofAPI dimer (D) is also haplotype specific.
3.3.3 Evaluation of the Effect ofDeglycosylation ofSpil and 3 on the Specificity and
Sensitivity ofmAb IB and 1.3.2
The isolated native glycosylated Spil isoforms (58kDa band) from all three
haplotypes (N, S and U) showed greater than 95% purity with small amounts of
contaminants of similar MWs (Figure 3.7). The two main products from
deglycosylation of the Spil isoforms are seen as 49.5 and 46 kDa bands. Examination
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of the Western blot probed with mAb IB reveals that the antibody recognises all the
glycosylated Spil isoforms from all three haplotypes and both of the deglycosylated
products (Figure 3.8). However, the N haplotype still immunostains less intensely
than those of S and U. This suggests that mAb IB recognises a peptide epitope which
is either less abundant or still, for some reason, less accessible to the antibody in the
Spil isoform of haplotype N. When an identical Western blot was probed with mAb
1.3.2 both the glycosylated and deglycosylated Spil isoforms of haplotype N were
just visible on immunostaining (Figure 3.9) compared to not at all when in serum
(Figure 3.6), those of haplotypes S and T were clearly recognised by this antibody.
These results suggest that mAb 1.3.2 also recognises a peptide epitope of Spil but
this epitope is even less abundant and/or accessible in haplotype N than the epitope
recognised by mAb IB.
97.4**—
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INN' S S' U U'
Figure 3.7 - Silver stained 10% SDS-PAGE under reducing conditions of purified
Spil proteins of haplotypes N, S and U and their respective deglycosylation products
N', S' and U\ MW markers (lane 1, kDa) show reduction in size of deglycosylated
proteins. Note two deglycosylation products of similar MW for each haplotype (lanes
N', S' and U'). PNGase F is a single chain protein with a MW of approximately 32
kDa which can be seen in the three lanes in which deglycosylated proteins have been
elecrophoresed (arrow).
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N DN S DS T DT
Figure 3.8 - Western blot made from a gel identical to that in Figure 3.7 probed with
mAb IB. Note the weaker positive staining for native Spil along with the
deglycosylation products in haplotype N (N and DN respectively) compared to that of
haplotypes S and T.
N DN S DS T DT
Figure 3.9 - Western blot made from a gel identical to that in Figure 3.7 probed with
mAb 1.3.2. The overall intensity of positive staining is less than that of mAb IB
(Figure 3.8) in all haplotypes. The glycosylated (N) and deglycosylated (DN) forms of
Spil from haplotype N were barely visible.
The purified glycosylated Spi3 from all three haplotypes gave a double band (MWs
64.5 and 61kDa) on 10% SDS-PAGE typical of this isoform (Figure 3.10). Again two
main deglycosylation products are evident (MWs 48 and 44kDa) for each haplotype.
Examination of the Western blot of the Spi3 isoforms probed with mAb IB reveals
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that both glycosylated and deglycosylated forms in all three haplotypes are recognised
(Figure 3.11).
INN' S S' U U'
Figure 3.10 - Silver Stained 10% SDS-PAGE under reducing conditions of purified
Spi3 proteins of haplotypes N, S and U and their respective deglycosylation products
N', S' and U\ Note two deglycosylation products of similar MW for each haplotype
(lanes N', S' and U') despite two glycosylated proteins in lanes N, S and U. Also
some glycosylated protein remains in sample exposed to PNGase F (arrow).
1
N DN S DS T DT
Figure 3.11 - Western blot made from a gel identical to that in Figure 3.10 probed
with mAb IB. Note the presence of a double band in both the glycosylated (N, S and
T) and deglycosylated forms (DN, DS and DT) in all three haplotypes examined.
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The relative level of staining intensity is similar to that in the blot made from sera
under native conditions and probed with mAb IB (Figure 3.5) in that the U haplotype
Spil protein stained most intensely followed by N and S respectively. However, the
absolute level of immunostaining was greater in the glycosylated Spi3 isoforms of
haplotypes N and S when subjected to electrophoresis under reducing conditions
(Figure 3.11) compared to native conditions (Figure 3.5). This would suggest that the
peptide epitope recognised by mAb IB is less accessible in the Spi3 isoform of
haplotypes N and S probably due to the tertiary structure of the amino acid chain
rather than being obstructed by the externally located triantennary CHO side chains.
The Western blot of the purified Spi3 isoforms probed with mAb 1.3.2 was devoid of
any immunostaining suggesting the peptide epitope recognised by this antibody is
probably absent in the Spi3 isoforms ofall 8 haplotypes examined (Figure 3.6).
3.4 Discussion
The classical chemical method for purification of API from serum is a laborious four
step procedure; (1) chromatography on blue Sepharose to remove albumin, (2)
ammonium sulphate precipitation, (3) anion exchange (Mono Q FPLC)
chromatography at pH 6.5 and (4) high resolution gel filtration (Superose 12 FPLC)
(Panned et al 1974). Despite its complexity the product of this method still suffers
from significant contamination with esterase. Equine API can, using immunological
means, be specifically and rapidly purified from serum by affinity chromatography in
the simple one step procedure described above (Scudamore et al 1994) with a purity,
as determined by Coomassie stained native PAGE, approaching 100%. Affinity
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purification allows large amounts of equine API to be obtained for use as a source of
immunising and characterising antigen as well as for use as a standard in ELISAs. The
affinity purified API is also the initial step in isolation of individual Spi proteins,
requiring one further step involving Mono Q anion exchange chromatography, for
more detailed characterisation of Spi specific antibodies.
Using affinity purified API, one polyclonal and two monoclonal antibodies specific for
equine API have been successfully raised and characterised. All three antibodies gave
consistent, repeatable specificities and sensitivities to the isoforms and haplotypes of
equine API in Western blots. Previous studies utilising antibodies raised to equine API
were unable to show their exact specificities by any of the accepted methods such as
Western blots (Winder et al 1989; Milne et al 1994c; Scudamore et al 1994). The
recognition by polyclonal sheep anti-equine API antibody of all Spi proteins with
virtually equal sensitivity on Western blots suggests this antibody may be a useful
tool; not only for the detection of total API present in tissues by
immunohistochemistry but also soluble API in complex biological solutions by
sandwich ELISA. The slight variations in the sensitivity of the polyclonal antibody to
individual Spi proteins in some haplotypes of API are probably due to variations in
Spi protein serum concentrations. API haplotypes F and L have been investigated by
video densitometry (Patterson et al 1991) to evaluate the serum concentrations of
their individual Spi proteins which have been shown to vary between the two
haplotypes examined (Table 3.2).
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Spi Protein Serum Concentration of Spi Protein (g/L)





4 0.8 Not Present
Table 3.2 - Variations in serum concentration of Spi proteins in two haplotypes of
equine API (from Patterson et al, 1991).
Both monoclonal antibodies in our study recognise peptide epitopes, suggesting that
with respect to their primary amino acid sequence there is a close antigenic
relationship between the 4 Spi proteins (mAb IB recognised all Spi proteins).
However, there is also detectable antigenic diversity in that mAb 1.3.2 recognised
only Spil and 2 and then only in certain haplotypes. The specificity of mAb 1.3.2
supports the suggestion of one study which partially characterised the amino acid
sequences of the Spi proteins, including those of the reactive site regions, and found
that all four proteins were closely related, but within the four there were two pairs
(Spil and 2 and Spi3 and 4) which were most strongly related (Patterson et al 1991).
The appearance of two protein products from purified Spil after PNGase-F treatment
suggests that not all of the CHO side chains have been removed during the overnight
incubation period. The native Spi3 isoform consists of two isoforms (Figure 3.10)
thought to have identical amino acid structures (Patterson et al 1991), the more acidic
isoform containing two additional terminal sialic acid residues which are thought to be
part of an extra complex biantennary CHO side chain (Patterson and Bell, 1986).
With Spi3, two products are also seen after overnight incubation with PNGase-F
suggesting, again, that incomplete deglycosylation occurs for some reason and also
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supporting the suggestion that the difference between Spi3A and Spi3B is in the CHO
side chains. This may be due to insufficient exposure time to the enzyme or some form
of structural and/or electrostatic hindrance from the tertiary structure of the Spi
proteins preventing complete deglycosylation.
In conclusion, the characterisation of the antibodies raised in this study suggests the
existence of antigenic relationships and differences between the Spi proteins of equine
API due to similarities and differences in the primary amino acid sequences. The
polyclonal antibody and mAb IB have the potential to be useful in further studies in to
the immunolocalisation and measurement of total equine API.
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Chapter 4
LOCALISATION OF EQUINE ALPHA-1-PROTEINASE
INHIBITOR BY IMMUNOHISTOCHEMISTRY
4.1 Introduction
Pulmonary emphysema in horses with neutrophil associated lung diseases, such as
chronic obstructive pulmonary disease (COPD), is restricted to a peribronchial pattern
of tissue destruction (Kaup et al 1990) compared to the relatively extensive
centrilobular pattern found in human lung tissue with similar neutrophil associated
pulmonary diseases (Creagh and Krausz, 1992) or panacinar destruction with API
deficiency (Laurell and Eriksson, 1963). Pulmonary emphysema has been shown to be
associated with unregulated NE activity arising from the balance of the
proteinase:anti-proteinase equilibrium being shifted in favour of the proteinase side of
the equation (Dubin et al 1994; Shapiro, 1995). This shift could be due to a decrease
in the anti-proteinase screen of the lower respiratory tract (LRT), an increase in the
proteolytic burden or a combination of the two. One explanation for the species
specific anatomical patterns of emphysema could be a difference in the anti-elastase
screen of the lower respiratory tract of horses and humans of which API is the main
component (Gadek et al 1981a). API found in the pulmonary epithelial lining fluid is
derived mainly from the plasma (Milne et al 1994c). Plasma API is synthesised in the
fiver (Carlson et al 1988; Hafeez et al 1992). However, local production of human
API occurs in alveolar epithelial cells (Venembre et al 1994), cornea (Twining et al
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1994), intestinal epithelium (Molmenti et al 1993), neutrophils (duBois et al 1991)
and monocytes and macrophages (Perlmutter et al 1985). Investigation of non-
pulmonary tissues may be necessary to evaluate the source and distribution of equine
API and its role in the anti-elastase screen with regard to the anatomical pattern of
equine pulmonary emphysema.
Human API has been extensively investigated in terms of its location in tissues and
sites of synthesis by immunohistochemistry (see Chapter 1.7) and detection of API
specific mRNA respectively. Development ofmRNA probes has been made possible
by reference to the known complete amino acid and gene sequences for human API.
Interestingly, in humans, despite molecular (Carlson et al 1988; Hafeez et al 1992)
and surgical transplantational studies (Alper et al 1980) proving plasma API to be
mainly derived from hepatocytes, it has proved difficult to immunolocalise API in the
normal Pi MM human fiver (Palmer et al 1974; Ray and Desmet, 1975; Palmer and
Wolfe, 1976; Palmer et al 1977; Ray et al 1977; Ray and Desmet, 1978; McElrath et
al 1979) with one exception (Feldmann et al 1976). Feldman et al. (1976) found 1-
5% of hepatocytes had homogeneous cytoplasmic staining for API by
immunohistochemistry.
The localisation of equine API has not been extensively studied. There is only one
report of tissue immunolocafisation and this was confined to the fiver, lung and
peripheral blood leukocytes (Winder et al 1989). Two groups have published limited
N-terminal amino acid sequences for the equine Spi proteins; one group found all Spi
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proteins to be identical for the first 32 amino acid residues examined (Potempa et al
1991b), the other found differences between all Spi proteins by residue 20 (Patterson
et al 1991). No data is available on the gene sequences of the equine Spi proteins and
it is therefore not possible at the current time to design primers for use in polymerase
chain reaction (Grainger and Madden, 1993) or in situ hybridisation protocols.
The aim of this study was to immunolocalise equine API in several equine tissues
using the sheep anti-equine API antibody and mAb IB in order to compare the
distribution pattern with that previously described for humans. Demonstration of
species specific differences in API distribution may help to explain the differences in
the anatomical patterns of pulmonary emphysema found in the two species in
neutrophil associated pulmonary disease.
4.2 Materials and Methods
4.2.1 Choice ofEquine Tissues for Immunohistochemistry
In keeping with the aims of this study, equine lung parenchyma and airways were
sampled. Since COPD is associated with a large influx of neutrophils into the lung,
peripheral blood leukocytes were evaluated for the presence of equine API.
Examination of liver was considered essential because it is the site of synthesis in all
other species critically examined, (Koj et al 1978; Carlson et al 1988; Koopman et al
1989; Hafeez et al 1992). Stomach, pancreas, small intestine and large intestine were
sampled because published data in man (Ray and Desmet, 1978; Kittas el al 1982;
Geboes et al 1982) made further comparisons between the two species possible.
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4.2.2 Tissue Sampling, Fixation, Storage and Preparation
Tissue and serum samples were obtained from 5 horses at post mortem following
clinical diagnoses of:- lameness (2), malignant ovarian tumour (1), behavioural
problem (1) and chronic hepatic failure (1). The group comprised 3 mares and 2
geldings, 4-13 years old, with a mean age of 7.6 years. Tissues were removed within
30 minutes of euthanasia, trimmed, and fixed in freshly prepared 4%
paraformaldehyde in phosphate buffered saline (PBS) for 24 hours. Samples were
then transferred to 70% ethanol and stored at 4°C until embedding in paraffin wax.
Sections (4pm) were mounted on TESPA coated slides and stored at 4°C.
Peripheral blood leukocytes were obtained by allowing citrated plasma to sediment
under gravity for 30 minutes at room temperature, revealing an upper leukocyte rich
plasma layer which was aspirated and centrifuged at 380 x g for 6 minutes. The
leukocyte rich pellet was washed four times in Dulbecco's PBS without calcium and
magnesium + 0.1% BSA to remove all non-cell associated equine API, followed by
resuspension at 5 x 106 leukocytes/ml after evaluation by an automated cell counter
(System 9000, Serono Baker Diagnostics, Pennsylvania, US). Eighty microlitre
samples (5 x 106 cells/ml) were centrifuged onto TESPA coated slides (3 minutes at
300 rpm, Shandon Cytospin 3, Southern Instruments Ltd., Runcorn, UK) and fixed in
freshly prepared 4% paraformaldehyde in PBS for 45 minutes at 45°C, transferred to
70% ethanol and stored at 4°C until required.
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4.2.3 Labelling ofSheep Anti-Equine APIAntibody with Horse Radish Peroxidase
Affinity purified sheep anti-ENE 2A antibodies and normal sheep IgG were
conjugated to horse radish peroxidase enzyme (HRPO). Their respective RZ values
were determined and they were stored as described in Chapter 2.12.1.
4.2.4 Immunohistochemical Localisation ofAPI with Sheep Anti-Equine API
Paraffin embedded equine tissue sections, mounted on TESPA coated slides, were
heated to 60°C in a drying oven for 30 minutes to soften the paraffin then dewaxed in
xylene and rehydrated to 95% ethanol. Endogenous tissue peroxidase activity was
blocked by exposing tissue sections to 3% H2O2 in methanol for 20 minutes followed
by washing in running tap water for 5 minutes. To improve the accessibility of API
antigens to the antibody, an antigen recovery step was incorporated into the
procedure at this point.
Initially attempts to improve antigenicity involved exposing sections to 0.1% trypsin
in 0.1% CaCl, pH 7.8 at 37°C for 20 minutes followed by two washes in PBS (5
minutes each) which resulted in little or no immunostaining of equine API in the
tissues examined by either antibody (data not shown). An alternative, successful,
procedure was employed whereby sections were exposed to a 0.01M citrate buffer
(Appendix 1), pH 6.0±0.1 at 95-100°C on a heated magnetic stirrer plate for 10
minutes and then allowed to cool at room temperature for a further 10 minutes (Lan
et al 1995) followed by two washes in PBS (5 minutes each).
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Sections were placed in a Sequenza™ Immunostaining Chamber (Shandon Inc.,
Pittsburgh, USA) and non-specific binding of the sheep anti-equine API antibody was
eliminated by incubating sections in 5% normal sheep serum (NSS) in PBS for 30
minutes immediately prior to addition of sheep anti-equine API antibody conjugated
to HRPO (1.25pg/ml in 5% NSS/PBS) for 90 minutes. Three washes in PBS (5
minutes each) preceded staining with a DAB peroxidase substrate kit (Vector
Laboratories, Peterborough, UK). On appearance of brown colouration (3-5 minutes)
sections were washed in running tap water for 2 minutes followed by counterstaining
of tissues in Mayer's Haematoxylin and blueing with Scott's Tap Water Replacement
(Appendix 1). Sections were initially mounted in Crystal/Mount™ (Biomeda corp.,
Foster City, CA, USA) then DPX and a coverslip applied. Negative control
preparations were treated identically except the sheep anti-equine APLHRPO
(RZ=0.700) was substituted with 1.17pg/ml of normal IgG:HRPO (RZ=0.750) in 5%
NSS/PBS.
Cytospin preparations were dehydrated in 95% ethanol and, after blocking
endogenous tissue peroxidase activity, they were treated identically to the tissue
sections, except that the antigen recovery procedure was omitted.
4.2.5 Localisation ofEquine API Using mAb IB and a Biotin Labelled Anti-Mouse
IgG Secondary Antibody
To confirm that mAb IB identified the API haplotypes of the 5 horses from which
tissue samples were taken, their sera were subjected to 11.2% native PAGE (with
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blue dextran incorporated into the stacking gel to retard albumin migration) and the
proteins transferred to Immobilon-P by Western blotting. The Western blot was
probed with mAb IB as described in Chapter 3.2.3.
The initial immunohistochemistry procedure with mAb IB was identical to that used
for the sheep anti-equine API antibody up to and including placing the sections in the
Sequenza™ (Shandon Inc., Pittsburgh, USA). However, the blocking solution when
using mAb IB was PBS + 0.5% Tween 80 (PBST80) applied for 30 minutes. For
liver sections this was followed by blocking of biotin by a Biotin/Avidin Blocking Kit
(Vector Laboratories, Peterborough, UK). All sections were then washed in PBS
followed by addition ofmAb IB at 80pg/ml in PBST80 for 90 minutes. Sections were
washed in PBS (3x5 minutes) followed by addition of goat anti-mouse IgG (Fab
specific) antibody conjugated to biotin (Sigma Chemical Co., B 7151) diluted 1/200 in
PBST80 for 60 minutes. Sections were washed in PBS (3x5 minutes) prior to
addition of a preparation of HRPO conjugated to avidin (Vector Elite ABC Kit,
Vector Laboratories, Peterborough, UK) as per manufacturer's recommendations for
30 minutes. Sections were washed in PBS (3x5 minutes) and incubated with 3-
amino-9-ethylcarbazole substrate (AEC Peroxidase Substrate Kit, Vector
Laboratories, Peterborough, UK) until a red pigment was seen (about 15 minutes)
then washed in running tap water (2 minutes). Counterstaining and mounting was
identical to that described above. Negative control preparations were treated
identically except mAb IB was replaced with normal mouse IgGj (MOPC 31c, Sigma
Chemical Co., M 9035) at 80pg/ml in PBST80.
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Cytospin preparations were again dehydrated in 95% ethanol and, after blocking
endogenous tissue peroxidase activity, they were treated identically to the tissue
sections probed with mAb IB, except that the antigen recovery procedure was
omitted.
4.3 Results
4.3.1 Recognition ofAPI Haplotypes by mAb IB
Monoclonal antibody IB recognises Spil & 2 in all five horses and Spi3 and dimer in
four out of five horses (Figure 4.1 & 4.2). The horse in which Spi3 and dimer were
not recognised by mAb IB contained a large amount of protein, probably from
haemolysed red blood cells (Figure 4.1). This may have masked recognition of Spi3
and dimer, or mAb IB may simply not recognise Spi3 in this particular phenotype.
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Figure 4.1 - Native 11.2% PAGE of sera from the 5 horses used for
immunohistochemistry. Note large amount of protein staining in lane 1 (arrow) which
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Figure 4.2 - Western blot made from a gel identical to Figure 4.1 probed with mAb
IB. D = dimer, numbers 1&2, 3A and 3B refer to Spi proteins. Note lack of staining
ofSpi3A, 3B and dimer in lane 1. The horses were euthanased due to; lameness, lanes
1 and 3, behavioural problem, lane 2, ovarian tumour, lane 4 and liver failure, lane 5.
4.3.2 Comparison ofSheep Polyclonal andmAb IB Immunohistochemistry
Positive staining for equine API in tissues was represented by red pigmentation (AEC)
when sections were probed with mAb IB, and brown pigmentation (DAB) with sheep
polyclonal anti-equine API antibody.
Blood vessel contents stain intensely positive for API in all tissues examined with
mAb IB or the sheep anti-equine antibody. Nuclei of cells in all tissues examined
(except peripheral blood leukocytes) were devoid of any API when probed with either
of the antibodies. Negative control slides, pair matched for each tissue examined in
each of the 5 horses, were devoid of any immunostaining
Lung parenchyma and bronchi. Lung parenchyma stained variably for API with both
antibodies (Figures 4.3 & 4.4). The cytoplasm of alveolar epithelium varied from
unlabelled to intensely positive. Intense staining of multiple cytoplasmic granules is
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more prominent with mAb IB, especially in Type II pneumocytes (Figure 4.5). The
most striking difference was the staining of cilia of bronchial columnar epithelium with
the sheep anti-equine antibody (Figure 4.6). Whereas, bronchial epithelial staining is
absent and only the occasional bronchial epithelial cell has positively staining
cytoplasm with mAb IB (Figure 4.7).
Figure 4.3 - Distribution of API in lung parenchyma after probing with mAb IB.
Note the variability from little or none to intense immunostaining (arrows) in some
areas (x 400).
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Figure 4.4 - Lung parenchyma probed with the sheep anti-equine API antibody. Very
similar pattern to sections stained using mAb IB, tissues vary from little to no positive
staining for API (black arrow) to intense staining in some places. Note capillary
contents staining intensely for API (blue arrow), (x 400).
Figure 4.5 - Alveolar wall probed with sheep anti-equine API antibody. Note the
intense staining of cytoplasm of a Type II pneumocyte (arrow), (x 1000).
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Figure 4.6 - Transverse section of bronchial airway stained using the sheep anti-
equine API antibody. Bronchial epithelium cilia stain intensely for API (black arrow)
as do blood vessel contents (green arrow) (x 400).
Figure 4.7 - Transverse section of airway epithelium evaluated for API distribution
with mAb IB. Cilia of airway epithelium show no immunostaining with mAb IB, only
the cytoplasm of occasional columnar epithelium cell is positive for API (arrow) (x
1000).
Chondrocytes contained within the lacunae of peribronchial cartilage all have intense
cytoplasmic staining with the sheep anti-equine API antibody (Figure 4.8) however
this is barely perceptible with mAb IB (not shown).
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Figure 4.8 - Transverse section of peribronchiolar cartilage stained using the sheep
anti-equine API antibody. Cytoplasm of chondrocytes within the lacunae of
peribronchiolar cartilage stain intensely for API (arrows) (x 400)
Liver. Cytoplasmic staining of hepatocytes was highly variable with both antibodies.
When present, staining was diffuse, with the most intensely staining cells having a
centrilobular distribution (Figure 4.9). Some hepatocytes appeared completely devoid
of API staining. Intra-cytoplasmic granules of differing size, single or multiple were
present in the cytoplasm of some hepatocytes, often in the perinuclear region and
grouped together (Figure 4.10). API granules stained more intensely with mAb IB
than with the sheep anti-equine API antibody (Figures 4.10 & 4.11). Intense staining
was present in the lumen of the bile ductules where contents were present with both
antibodies. The cytoplasm of bile ductule epithelium stained variably for API with the
sheep anti-equine API antibody, but intensely with mAb IB, particularly at the apices
of the cells (Figure 4.12- 4.15).
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Figure 4.9 - Transverse section of liver through a central vein stained for API using
mAb IB. Note centrilobular distribution of the more diffuse cytoplasmic API
immunostaining and the widely distributed granular intracytoplasmic inclusions
(arrows) (x 250).
Figure 4.10 - Higher power micrograph showing variable staining for API with mAb
IB. Some cells lack API (black arrow). In many cells API is concentrated in large
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Figure 4.11 - Liver tissue probed with the sheep anti-equine API antibody. API
granules (arrows) are less prominent with this antibody and diffuse hepatocyte
cytoplasmic staining more consistent between hepatocytes than with mAb IB (x
1000).
Figure 4.12 - Transverse section of a hepatic bile ductule stained for API using mAb
IB. API is localised in the epithelium (black arrow). A small capillary (green arrow)


















Figure 4.13 - Transverse section of a hepatic bile duct. Negative control preparation
in which an identical amount of mouse IgGi (MOPC 31c) was substituted for mAb
IB. No specific staining for API is present (x 1000).
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Figure 4.14 - Transverse section of a large hepatic bile ductule probed with the sheep
anti-equine API antibody. Note the presence ofAPI in the lumen (x 250).
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Figure 4.15 - Transverse section of a large hepatic bile ductule. Negative control
preparation, the section is devoid of any specific staining (x 250).
Stomach. Luminal mucus, mucous neck cells and lamina propria ground substance are
positive for API with both antibodies (Figures 4.16 & 4.17). Using mAb IB,
cytoplasm of peptic, parietal and gastric pit cells is variably positive for API,
occasional peptic cells display intense granular staining.
Figure 4.16 - Transverse section of gastric mucosa stained for API using mAb IB.
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Figure 4.17 - Oblique section of gastric wall probed with the sheep anti-equine API
antibody. A more extensive distribution of API is seen throughout the gastric wall
cells though some do not stain for API (x 250).
Pancreas. There was intense and uniform localisation ofAPI in the cytoplasm of cells
in the Islets of Langerhans with both antibodies (Figures 4.18-4.23). Pancreatic duct
contents and the cytoplasm of duct columnar epithelial cells were positive for API
with both antibodies, mAb IB producing a uniformly stippled pattern. Frequent,
solitary, very large intensely staining granular inclusions are seen in the basal
cytoplasm of these cells (Figures 4.24). Occasional cells throughout the pancreatic
parenchyma also had positive cytoplasmic staining especially if in close proximity to
large blood vessels.
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Figure 4.18 - Pancreatic tissue probed for API with mAb IB. All Islets of Langerhans
are intensely stained for API (black arrows) along with blood vessels (green arrows)
and occasional parenchymal cells (x 100).
Figure 4.19 - Negative control preparation in which an identical amount of mouse
IgGi (MOPC 31c) was substituted for mAb IB. No specific staining is present in the
pancreas (x 250).
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Figure 4.20 - Pancreatic tissue probed for API with the sheep anti-equine APLHRPO
antibody. The pattern of immunostaining is identical to that with mAb IB (see Figure
4.18). Islets of Langerhans (black arrows), blood vessels (red arrows) (x 250).
Figure 4.21 - Negative control preparation for sheep anti-equine API:HRPO
antibody. The section is devoid of any specific staining (x 250).
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Figure 4.22 - Pancreatic tissue stained for API using mAb IB. Note intense stippling
of the cytoplasm of all Islet of Langerhan cells (x 1000).
Figure 4.23 - Pancreatic tissue probed with the sheep anti-equine API antibody. The
API distribution pattern is similar to that of mAb IB except it does not have the
stippled appearance (x 400).
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Figure 4.24 - Transverse section of pancreatic duct probed with mAb IB. Note large
intensely staining granules at the base of pancreatic duct columnar epithelial cells
(arrows). The star denotes the lumen of the pancreatic duct (x 1000).
Jejunum. The lamina propria along with the cytoplasm of some columnar epithelial
cells, most microvilli and occasional submucosal glands are positive for API with both
antibodies (Figures 4.25). Goblet cell mucus, however, stained more intensely with
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Figure 4.25 - Transverse section of jejunal villi stained for API using mAb IB. Note
the Goblet cell mucus is devoid ofAPI (arrows) (x 250).
107
Colon. Intense uniform staining of the luminal surface, Goblet cells, plus the mucus
and cytoplasm of some columnar epithelial cells was found with the sheep anti-equine
API antibody (Figure 4.26 & 4.27). However, with mAb IB only weak stippled
staining of the cytoplasm of some colonic columnar epithelial cells was seen. Goblet
cell mucus was rarely positive.
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Figure 4.26 - Longitudinal section of colon stained for API with the sheep anti-
equine API antibody. Note abundant immunostaining of API of goblet cell mucus
(arrows) (x 250).
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gure 4.27 - Negative control preparation of colonic tissue for sheep anti-equine
PLHRPO antibody. The section is devoid of any specific staining (x 250).
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Neuronal Tissue. Sub-bronchial neuronal tissue which was found only on one section
appeared to have a sheath of API surrounding individual nerve bundles when probed
with mAb IB (Figure 4.28 & 4.29).
Figure 4.28 - Transverse section of sub-bronchial neuronal bundle stained for API
using mAb IB. Neurones (black arrows) appear bathed in a sheath of API (green
arrows) (x 100).
Figure 4.29 - Negative control preparation in which an identical amount of mouse
IgGi (MOPC 31c) was substituted for mAb IB as a negative control preparation. The
section was devoid of any specific staining (x 100).
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Peripheral Blood Leukocytes. Cytosmears of leukocytes were stained with DAB
irrespective of whether mAb IB or sheep anti-equine AP1HRPO antibody was used
to localise API. Neutrophils had the most intense immunostaining for equine API
compared to other leukocytes with a general diffuse cytoplasmic pattern (Figure 4.30
& 4.31). The nuclear membrane appears to stain for equine API but this could be API
within the perinuclear cysternum. Monocytes also had faint cytoplasmic and nuclear
membrane staining for equine API. The results for peripheral blood leukocytes were
identical with both antibodies.
Figure 4.30 - Cytosmears of peripheral blood leukocytes stained for API using mAb
IB. Neutrophils are clearly identifiable by their multilobular nuclei (black arrows).
Positive staining for API is represented by brown pigmentation (DAB) and can be
seen in the cytoplasm of neutrophils when compared to the negative control
cytosmear below (Figure 4.31). Monocytes (red arrows) show very faint staining for
API in both their cytoplasm and perinuclear region (x 1000).
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Figure 4.31 - Negative control preparation in which an identical amount of mouse
IgGi (MOPC 31c) was substituted for mAb IB. No specific immunostaining for API
is present (x 1000).
Summary of Immunolocalisation of API. No difference was seen in the
immunostaining pattern or intensity of sections from the horse whose Spi3 was not
recognised by mAb IB on the Western blot suggesting the haemolysed red blood cells
may have affected the recognition of Spi3 rather than the antibody being unable to
detect it. The horse which was euthanased due to liver failure had extensive hepatic
fibrosis, however, where present, hepatocytes had a similar distribution pattern of API
as samples from the other four horses (data not shown). Except for this single
exception, all tissues from all 5 horses displayed identical distribution patterns for
equine API when the same antibody was used. A comparison of the tissue
immunostaining patterns ofAPI with the two different antibodies is seen in Table 4.1.
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Tissue Sample Sheep anti-equine mAb IB"
API antibody"
Blood vessel contents ++++ ++++
Hepatocyte cytoplasm ++++/++ +++/++
Hepatocyte cytoplasmic granules ++ ++++
Bile ductule epithelium ++/- +++
Bronchial epithelium cilia ++++ -
Peribronchial cartilage chondrocytes +++ +/-
Islets of Langerhans ++++ ++++
Pancreatic duct epithelium +++ ++++
Colon Goblet cells +++ +/-
Colon columnar epithelium ++ +/-
Sub-bronchial neuronal tissue ND ++
Table 4.1 - Comparison of the Range of immunohistochemical staining intensity" in
different tissues with the sheep anti-equine API antibody and mAb IB to equine API.
"
no staining; +, ++, +++ and ++++, weak, medium, strong and intense staining,
respectively. ND = not determined.
4.4 Discussion
Previous studies of equine API have highlighted its relative complexity in terms of the
multiple isoforms (Spi proteins) found in each individual horse (Patterson et al 1991;
Potempa et al 1991b) compared to the single isoform of API present in each human
(Gadek and Crystal, 1983; Cox, 1989). Differences in functional properties have also
been documented (Fagerhol and Cox, 1981; Patterson et al 1991; Potempa et al
1991b). This, however, is the first investigation to immunolocalise equine API with
antibodies whose specificities have been extensively characterised by Western
blotting, both to the affinity purified antigen (equine API) and to the antigen in the
presence of other serum proteins. It is also the first time some equine tissues
(stomach, pancreas, jejunum and colon) have been investigated for the presence of
equine API by any method. It must be borne in mind that immunolocalisation of
equine API in a tissue or cell type does not denote synthesis, but a similar
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immunostaining pattern to human tissues in which synthesis has been proven by
detection of API specific mRNA would suggest the possibility of local production in
the horse in the absence of specific equine API mRNA probes.
The boiling citrate antigen recovery procedure (Lan et al 1995) was an essential step
in the immunolocalisation of equine API in all paraffin embedded tissues examined.
Initial attempts at antigen recovery by subjecting sections to trypsin, which has been
frequently employed in many other immunolocalisation studies, were unsuccessful
suggesting that the equine API antigens might be susceptible to proteolytic cleavage
or resistant to exposure by enzymatic digestion of surrounding tissues. Another
possibility is that the equine API present in paraformaldehyde fixed, paraffin
embedded sections may still possess inhibitory activity thereby binding to the trypsin
(a serine proteinase known to be inhibited by native human API) which might result in
reduced accessibility to its antigenic epitopes rather than enhancing it.
The sheep anti-equine API antibody and mAb IB show considerable similarities in the
localisation of equine API. The main difference was that mAb IB gave a more
granular staining pattern. The polyclonal sheep anti-equine API antibody will
recognise multiple antigenic epitopes on the equine API molecule resulting in more
than one antibody molecule binding to each API molecule leading to an enhancement
of detected signal. The monoclonal antibody, however, will probably only recognise a
single antigenic epitope which may only occur once on each API molecule. The latter
will result in poorer detection of diffusely distributed API compared to granular
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accumulations of protein. This may explain why mAb IB appears to give a more
granular pattern than the sheep anti-equine API antibody in many tissues.
The most striking difference between the staining patterns of the sheep anti-equine
API antibody and mAb IB was found in the lungs. Intense staining of the cilia of
bronchial columnar epithelium with the sheep anti-equine API antibody (Figure 4.6) is
completely absent with mAb IB. This could be explained by a variation in antibody
sensitivity as described above, however, the difference is so great that the sheep anti-
equine API antibody may detect a serpin not recognised by mAb IB. Similar
disparities were seen when the chondrocytes contained within the lacunae of
peribronchial cartilage (Figure 4.8) and mucus within goblet cells of the colon (Figure
4.26) were stained and compared.
Type II pneumocytes, which were intensely positive for equine API in this study
(Figure 4.5), have been shown in humans (using the A549 cell line which is used as a
model of human type II pneumocytes), by Northern blot analysis the presence of
human API specific transcripts (Venembre et al 1994) which is taken to indicate
protein synthesis. This suggests that synthesis of equine API from type II
pneumocytes might also occur in the horse. It has also been shown that human
bronchial epithelial cells synthesise and secrete API (Cichy et al 1997). However,
equine API was not detected in bronchial epithelial cells by immunostaining, only in
the cilia of the cells and then only by the sheep anti-equine API antibody (Figure 4.6).
The intracellular distribution of API in human bronchial epithelium has not been
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investigated. Nevertheless, biochemical studies show that human bronchial epithelial
cells synthesise API with glycosylation patterns which differ from API synthesised by
human HepG2 hepatocytes. The latter has a mixture of 3 isoforms of variably bi and
tri-antennary glycosylated proteins whereas that from human bronchial derived
epithelium contained all tri or tetra-antennary CHO side chains (Cichy et al 1997). If
an analogous situation exists in the horse and the CHO side chains are significantly
different from those of serum derived API (which was used to characterise both
antibodies used in this study) it may reduce the sensitivity of immunodetection by
physically or electrostatically blocking antibody access. This could explain why the
sheep anti-equine antibody with its multi-epitope specificity immunolocalises equine
API in the cilia of bronchial epithelium but mAb IB does not.
Equine hepatocytes appear to be the major source of plasma API in the horse due to
the extensive immunostaining and this is supported by the data from human (Carlson
et al 1988; Hafeez et al 1992), rat (Koj et al 1978) and mouse studies (Koopman et al
1989). Where present, equine API immunostaining in hepatocytes has two distinct
patterns, diffuse and granular. The diffuse cytoplasmic staining may be indicative of
synthesis in the endoplasmic reticulum with the granules in the perinuclear region
suggestive of post-translational modification and packing in the Golgi complex prior
to export from the cell.
WTien compared with previous studies of human liver (Palmer et al 1974; Ray and
Desmet, 1975; Palmer and Wolfe, 1976; Palmer et al 1977; Ray et al 1977; Ray and
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Desmet, 1978; McElrath et al 1979), equine hepatocytes show extensive
immunostaining for API. This indicates either a difference in the absolute levels of
hepatic API between the two species or some significant variation in methodology.
Circulating plasma concentration of equine API (3.5g/l) are high when compared to
human plasma API (1.3g/l). This may be due to a greater amount of synthesis per
hepatocyte, hence a greater amount ofAPI per cell. This in turn may result in a level
of API in the horse above the threshold detectable by immunohistochemical means,
whereas in the human the level may be below this threshold, possibly due to rapid
synthesis and secretion of API in the human hepatocyte, so that immunodetection is
not possible.
Human API immunolocalisation studies of liver biopsies used a variety of tissue
fixatives and rarely employed an antigen recovery step in the procedure, which, if
present, usually consisted of exposure to trypsin, the results of which this study found
disappointing. The use of a more sensitive technique, paraformaldehyde fixation
producing less cross linking of proteins combined with a better antigen recovery
procedure was found to give superior results.
The intense immunostaining of the Islets of Langerhans in the pancreas suggests a
large amount of equine API is present which has been previously proposed to have an
anti-enzymatic function (Ordonez et al 1985). It has been suggested that this is to
protect the delicate protein hormones insulin and glucagon produced in these cells
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from the actions of proteolytic enzymes such as trypsin (a serine proteinase inhibited
by API) which is produced in the surrounding parenchyma along with many other
proteolytic enzymes for use in intestinal digestion (Bendayan and Ito, 1979; Gauldie
et al 1980). The pancreatic ducts which transport the proteolytic enzymes to the
digestive tract have columnar epithelial cells that contain large amounts ofAPI, some
in granular form (Figure 4.24), presumably as protection against proteolytic enzyme
damage also.
Human pancreatic studies only show immunostaining ofAPI in the peripheral cells of
the Islets of Langerhans (Ray et al 1977; Ray and Desmet, 1978) which is again
probably a difference in methodology rather that a true difference in distribution.
Although the horse has a relative over abundance of API proteins compared to
humans, the similarity of the tissue distribution in the two species suggests that the
sites of local production of API in humans are likely to be present in the horse too.
However, until specific mRNA probes are available for equine API this will be
difficult to verify.
In conclusion this study has found that, with the exception of the liver, there is little or
no difference in the tissue distribution of immunolocalised API between horses and
humans in the tissues so far examined. This suggests that the specific location of API
in equine tissues is, in itself, unlikely to be responsible for the differences observed in
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the anatomical patterns of emphysema encountered in horses and humans in
neutrophil associated pulmonary diseases.
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Chapter 5
IMMUNOLOCALISATION AND QUANTITATION OF
ELASTASE IN EQUINE PERIPHERAL BLOOD NEUTROPHILS
5.1 Introduction
Equine peripheral blood neutrophils are believed to contain significantly less NE
(0.4pg/cell) (Dubin and Koj, 1986) than human neutrophils (1.1pg/cell) (Tetley et al
1989). The lower elastase content of equine neutrophils, combined with the greater
plasma concentration of API in the horse (Patterson et al 1991) (compared to
humans), may result in a more efficient anti-elastase screen/less potent proteolytic
capacity in the lower respiratory tract ofhorses compared to humans.
The NE content of peripheral blood neutrophils have been estimated by different
techniques in the two species; cell extracts from purified neutrophils were evaluated
for elastinolytic activity in horses (Dubin and Koj, 1986) versus a specific competitive
ELISA for HNE, independent of elastase activity, for humans (Tetley et al 1989).
However, we have shown immunocytochemically that API, the major inhibitor ofNE
in the lower respiratory tract (Gadek et al 1981a), is present in the equine neutrophil
(Chapter 4.3.2). It has also been shown that API found in human peripheral blood
neutrophils, where it can be synthesised by the mature cells, is capable of inhibiting
the HNE released from the cells (duBois et al 1991). Other studies have identified an
elastase inhibitor confined to the cytoplasm of equine neutrophils, horse leukocyte
elastase inhibitor (HLEI), present at a concentration of 0.5pg/cell (Dubin and Koj,
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1986) which interacts with equine neutrophil elastase with a KaSS = 107 M~V, Kj =
1010 M, forming inhibitory complexes which are stable on SDS-PAGE (Dubin and
Hauck, 1981; Dubin et al 1985; Dubin et al 1986).
The presence of these two inhibitors, API and HLEI, suggests that the evaluation of
the NE content of equine peripheral blood neutrophils by a method dependent upon
elastinolytic activity of cell extracts may underestimate the true concentration ofENE
as a proportion may be inhibited during the extraction process and thus not be
detected.
Equine neutrophil elastase consists of two major proteinases ENE 2A and ENE 2B
(Chapter 1.4), which have been shown to have different N-terminal amino acid
sequences, molecular weights, elastinolytic activities, isoelectric points and relative
proportions in the neutrophil (Dubin and Koj, 1986; Dubin et al 1994). ENE 2A is
reported to be three times more abundant than ENE 2B (Dubin and Koj, 1986) and
recent studies of equine APEENE interactions and functions have used ENE 2A
(Scudamore et al 1993; Pemberton et al 1993). Due to the greater potential yield of
ENE 2A during purification procedures and its prior use in proteinase:anti-proteinase
studies ENE 2A has formed the main focus of this study.
The aim of this study was to evaluate the concentration and distribution ofENE 2A in
equine peripheral blood neutrophils in order to assess the proteinase side of the
proteinase:antiproteinase equilibrium in the horse. Specifically to:
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i) purify equine neutrophil elastase 2A,
ii) using immunological techniques develop a specific method of detecting and
measuring ENE 2A in complex biological samples whether in the free
or complexed state,
iii) show the presence and distribution pattern ofENE 2A in equine peripheral
blood neutrophils by light microscopy and
iv) evaluate the relationship between the distribution ofENE 2A and that of
intracellular API in the neutrophil.
5.2 Materials and Methods
5.2.1 Production ofa Sheep Polyclonal Antibody to ENE 2A
Purification of ENE 2A. ENE 2A was extracted from equine peripheral blood
neutrophils by a modification of a previously published method (Dubin et al 1976).
Six litres of equine whole blood were collected immediately post mortem (from one
adult gelding) into sterile bottles containing 100ml 1.36% ethylene-diamino-
tetraacetic acid (EDTA) in PBS per litre of blood. Free sedimentation under gravity
for 45 minutes revealed an upper leukocyte rich plasma layer which was aspirated and
centrifuged at 600 x g, 4°C for 15 minutes to pellet the leukocytes. From this stage
onwards all samples were kept on ice. The supernatant was carefully removed without
disturbing the cell pellet and replaced with 36ml of sterile water for 20 seconds, to
remove any remaining red blood cells by hypotonic lysis. This was immediately
followed by addition of 12ml 3.6% NaCl to restore the solution to physiological
osmolality. The resultant cell suspension was centrifuged at 700 x g, 4°C for 10
121
minutes followed by careful removal of the dark red supernatant. The cell pellet was
resuspended in 60ml of PBS, centrifiiged at 700 x g, 4°C for 10 minutes, followed by
removal of the supernatant and resuspension of the cell pellet in 240ml of 0.2M
sucrose solution with heparin (150iu/ml). The suspension was then split into 10ml
aliquots which were homogenised (Ultra-Turrax T25, narrow probe, Fisher Scientific,
Leicestershire, UK) for 20 seconds to disrupt leukocytes. If the suspensions were still
very viscous samples were homogenised for a further 20 seconds. Aliquots were
pooled and centrifuged at 2000 x g, 4°C for 25 minutes to pellet cell debris and leave
the cytoplasmic granules (which contain ENE) in suspension. The supernatant was
removed and centrifiiged at 20000 x g, 4°C for 30 minutes to pellet granules. Granule
pellets were pooled and washed twice in 10ml of 0.3M sucrose and were centrifuged
each time at 20000 x g, 4°C for 30 minutes. The granule pellet could be stored at -
70°C at this point before being subjected to further extraction processes, if required,
or used immediately.
The granule pellet was suspended in 30ml of 1M NaCl, 0.05% Triton X 100 and
stirred overnight at 4°C in a glass universal to disrupt granules, causing release of their
enzymatic contents. The mixture was diluted 1:6 with 50mM 2-[N-Morpholino]
ethanesulphonic acid (MES) buffer, pH 6.0, 0.1% polyoxyethylene 23 lauryl ether
(BRIJ 35) to reduce the salt concentration (-0.14M). The mixture was centrifiiged at
20000 x g, 4°C for 30 minutes to obtain a clear supernatant containing elastase which
could be stored in 50ml aliquots at -20°C before the next stage in purification, if
required.
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The above supernatant, containing ENE 2A and 2B was subjected ion-exchange
chromatography using FPLC and a twin buffer system:
Buffer A 50mM MES, pH 6.0, 0.1%BRIJ
Buffer B 50mM MES, pH 6.0, 1M NaCl, 0.1% BRIJ
A Resource-S (strong cation) column (Pharmacia, Uppsala, Sweden) was equilibrated
with 95% Buffer A + 5% Buffer B at 4ml/minute. The above granule extract was
diluted 1:1 with Buffer A and loaded on to the Resource-S column followed by
equilibration with the original buffer mixture. To elute the bound proteins a gradient
of 5-60% Buffer B was applied to the loaded Resource-S column over 20 minutes.
The elastases elute as two major separate peaks between 20-30% Buffer B with ENE
2A eluting first and having a peak three times larger than that of ENE 2B. Fractions
were collected on the basis ofUV absorbance and temporarily stored at 4°C.
To purify the ENE 2A, the eluate from the Resource-S column corresponding to this
fraction was diluted with an equal volume of Buffer A and applied to a Mono-S
(strong cation, with smaller bead size that Resource-S) column (Pharmacia, Uppsala,
Sweden) equilibrated with 90% Buffer A + 10% Buffer B at 1ml/minute. Following
loading of the sample the buffer gradient was then altered from 10-60% Buffer B over
40 minutes with the ENE 2A eluting as the highest detectable peak at around 20%
Buffer B. Fractions were collected into separate test tubes every 60 seconds and those
corresponding to the large protein peak were subjected to 12% SDS-PAGE and silver
stained to assess purity. Samples were stored at -50°C.
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For the final purification step, the fractions most enriched for ENE 2A were subjected
to molecular weight exclusion chromatography by HPLC on a Supadex 75 column
(Pharmacia, Uppsala, Sweden) equilibrated with PBS, 0.5M NaCl, 0.1% BRIJ, 0.05%
sodium azide. Fractions were collected upon visualisation of UV absorbance and
subjected to 12% SDS-PAGE followed by staining with Coomassie brilliant blue (R-
250) to assess protein purity.
Antigen Inoculation Procedure. To prepare antibodies which would recognise ENE
2A in the complexed as well in the native free state, 50pg of purified ENE 2A was
incubated with 100pg of affinity purified equine API in PBS for 30 minutes at room
temperature (21°C) to allow complex formation. The solution of ENE 2A:API
complex was combined with adjuvant and inoculated using an identical protocol to
that for raising the polyclonal sheep anti-equine API antibody (Chapter 3.2.1).
Purification of Polyclonal Sheep Anti-ENE 2A Antibody. Sheep polyclonal antibodies
were purified by affinity chromatography as described for sheep anti-equine API
antibodies (Chapter 3.2.1). However, in this case, lmg of purified ENE 2A was used
as the ligand (see Chapter 2.8). The affinity purified anti-ENE 2A antibodies were
desalted, quantified and stored as previously described (Chapters 2.4.1 and 3.2.1).
5.2.2 Isolation ofEquine Peripheral Blood Leukocytes
pcjujpe peripheral blood neutrophils were isolated by modification of a previously
polished method using a discontinuous Percoll gradient and centrifugation which
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separates cells according to their density (Haslett et al 1985). All blood was taken by
jugular venipucture and anticoagulated with 1ml of 3.8% sodium citrate (Phoenix
Pharmaceuticals Ltd., Gloucester, UK) per 10ml of blood. Free sedimentation under
gravity for 30 minutes at room temperature revealed an upper leukocyte rich plasma
layer which was aspirated and centrifuged at 380g for 6 minutes. Platelet-rich plasma
supernatant was decanted and centrifuged at 2400g for 20 minutes to prepare platelet
poor plasma (PPP). The initial leukocyte rich pellet, obtained typically from 80ml of
whole blood, was resuspended in 2ml PPP in a 15ml polystyrene tube. This was
underlayered initially with 2ml of a 42% solution of 90% Percoll (90% Percoll, 10%
sterile 0.9% NaCl)/58% PPP followed by 2ml of 52% x 90% Percoll/48% PPP layer.
The resultant discontinuous gradient comprising leukocytes in PPP, 42% Percoll and
52% Percoll from top to bottom was centrifuged at 255g for 12 minutes at 21°C.
Two tight bands were resolved, cytospins prepared from these revealed that the
mononuclear cells were retained in the PPP/42% Percoll interface and neutrophils in
the 52%/42% interface. Neutrophils harvested from this layer were washed
sequentially in PPP, 4 times in Dulbecco's PBS without calcium and magnesium/0.1%
BSA and once in Dulbecco's PBS with calcium and 0.1% BSA prior to resuspension
in the latter. All procedures were performed at room temperature (21°C). Purity was
assessed by differential count ofDiff-Quik™ stained cytospins and cells counted by an
automated cell counter (System 9000, Serono Baker Diagnostics, Pennsylvania, US).
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5.2.3 Characterisation of the Sheep Anti-ENE 2A Antibody
The specificity of the sheep anti-ENE 2A antibody was evaluated by probing Western
blots ofENE 2A. Neutrophil extracts were prepared from pellets of 126 x 106 Percoll
purified equine peripheral blood neutrophils by the addition of 200pl 3M NaCl and
400pl SDS-PAGE reducing or non-reducing sample buffer (Chapter 2.5.1) and
repeated freeze thawing (5 cycles). The sample containing reducing buffer was heated
to 95°C. Both samples were centrifiiged (20000g, 30min. at 4°C) to remove DNA
and other cell debris and neutrophil extracts were stored at -70°C until required.
Purified ENE 2A (0.5pg per lane), neutrophil extract (20pl of the above preparation
per lane), APEENE 2A complex (1.0pg:0.5pg respectively per lane) and API (l.Opg
per lane) were separated by 10% SDS-PAGE under reducing and non-reducing
conditions to give several identical gels. One gel (reducing conditions) was stained
with Coomassie brilliant blue (R-250) to visualise all proteins present. Proteins from
similar gels (under reducing conditions or non-reducing conditions) were transferred
to Immobilon-P by semi-dry Western blotting (Chapter 2.7). Membranes were probed
with the either affinity purified sheep anti-ENE 2A antibody (see below) or with mAb
IB (anti-equine API) as described in Chapter 3.2.3.
For the sheep anti-ENE 2A antibody, non-specific binding on Western blots was
blocked with 3% dried skimmed milk (J.S. Sainsbury, London, UK) in PBS
(3%MPBS) for 60 minutes prior to addition of the primary antibody at 5pg/ml (in
3%MPBS) for 60 minutes. Following 3 washes in PBS + 0.05% Tween 20 and one in
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PBS respectively, for 5 minutes each, donkey anti-sheep IgG:HRPO conjugate (Sigma
Chemical Co., A 3415) at 1/4000 dilution in 3% MPBS was added for 60 minutes. An
identical wash procedure as before was then followed by addition ofDAB peroxidase
substrate kit (Vector Laboratories, Peterborough, UK) as per manufacturer's
instructions to visualise conjugated antibody. On appearance of protein bands the
membranes were washed in 3-4 changes of dEt20, photographed and subsequently
dried on filter paper prior to storage in a light proof container. An identical procedure
was performed on an identical control Western blot except the primary antibody was
substituted with 5pg/ml of normal sheep IgG.
5.2.4 Assessment ofProteolytic Activity ofPurifiedAntigens
Proteolytic activity of purified ENE 2A, neutrophil extract, APLENE 2A complex
and API was assessed by incorporating 20mg azocasein per lOmls of resolving gel
solution in 10% SDS-PAGE under non-reducing conditions (Horie et al 1984) as
described in Chapter 2.6.4. Sample loading was as described above in 5.2.3.,
proteolysis being seen as a clear band on the blue background of the gel.
5.2.5 Immunolocalisation of ENE 2A in Peripheral Blood Leukocytes Using Sheep
Anti-ENE 2A Antibody
Cytospins ofperipheral blood leukocytes were prepared, fixed and stored as described
in Chapter 2.15. Staining consisted of an identical procedure to that described in
Chapter 4.2.4 except the blocking solution was 5% normal rabbit serum in PBS
(5%NRS/PBS). The primary anti-ENE 2A antibody used in this study was diluted to
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1.25 |ug/ml in 5%NRS/PBS, the conjugate (rabbit anti-sheep IgG:HRPO, Dako Ltd.,
High Wycombe, Bucks, UK) was diluted 1/400 in 5%NRS/PBS and the peroxidase
substrate was AEC (Vector Laboratories, Peterborough, UK) added as per
manufacturer's instructions. On appearance of red coloration (about 9 minutes)
sections were washed, counterstained and mounted as described in Chapter 4.2.4.
Negative control preparations were treated identically except the sheep anti-ENE 2A
was substituted with an identical concentration of normal sheep IgG (Sigma Chemical
Co., I 5131), 1.25pg/ml in 5% NRS/PBS.
5.2.6 Colocalisation of ENE 2A and API in Peripheral Blood Leukocytes by Dual
Immunofluorescence
Conjugation of sheep anti-ENE 2A antibody to Cy3™ and sheep anti-equine API
antibody to fluorescein isothiocyanate (FITC) was performed as described in Chapter
2.12.2. Cytospins identical to those used for immunocytochemistry above were
rehydrated and exposed to DAB 4mg/10ml PBS, 50pl H202 (30% w/w) for 15
minutes to quench endogenous tissue fluorescence followed by three 5 minute washes
in dH20 and three in PBS respectively. Non-specific binding of antibodies was
blocked by addition of 5%NSS/PBS for 30 minutes. The primary antibodies were
added together in a total volume of 80pl per slide at final concentrations of 5pg/ml
and 7pg/ml for sheep anti-ENE 2A antibody and sheep anti-equine API antibody
respectively in 5%NSS/PBS for 90 minutes. Following three 5 minute washes in PBS
cytospins were mounted in Vectashield (Vector Laboratories, Peterborough, UK), a
coverslip applied and sealed with nail varnish.
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Negative control cytospins were treated identically except the primary antibodies were
substituted for two preparations of normal sheep IgG conjugated to Cy3 and FITC
with their respective concentrations altered for their fluorochrome to protein ratios.
5.2.7 Determination of the Amount of ENE 2A in an Equine Peripheral Blood
Neutrophil by a Specific Sandwich ELISA
Development of a Specific Sandwich ELISA to Measure ENE 2A. Micro-ELISA
plate wells (Dynex Technologies, Billingshurst, West Sussex, UK) were coated with
50pl of affinity purified sheep anti-ENE (1.5pg/ml) in 0.1M carbonate/bicarbonate
buffer (Appendix 1). After incubation at 4°C overnight, plates were washed 6 times
with 0.9% NaCl containing 0.05% Tween 20 (0.9% NaCl-T20). Samples (in
duplicate) and standards (in triplicate) were diluted in 5%MPBS containing 0.05%
Tween 20 (5%MPBST20), 50pl of each standard or sample were added per well.
Purified ENE 2A was used as a standard over the range 0.5 to 4.0 ng/ml. After
addition of samples and standards, plates were incubated at room temperature (21°C)
for 1 hour followed by washing 6 times in 0.9% NaCl-T20. Fifty microlitres of affinity
purified sheep anti-ENE 2A conjugated to HRPO (lpg/ml in 5%MPBST20, see
Chapter 2.12.1) was added per well and plates incubated for a further hour at room
temperature followed by a final 6 washes in 0.9% NaCl-T20. To initiate colour
development 50pl of TMB (Dynex Technologies, Billingshurst, West Sussex, UK)
was added per well as a soluble substrate for the HRPO enzyme and the reaction
terminated by addition of25pi of 0.18M H2SO4. The colour intensity was measured at
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490nm on a MR7000 ELISA plate reader (Dynex Technologies, Billingshurst, West
Sussex).
To evaluate the intra ELISA plate variation one row of blanks and three rows of
standards were applied to a plate as usual. To the remaining 64 wells 50pl of an ENE
2A solution, from a large single quality control batch diluted to be in the middle of the
standard curve, were added. The plate was developed in the usual manner and the
consistency of the OD values examined by coefficient of variance (see below). Inter
ELISA plate variations were assessed by adding 50pi of the above quality control
ENE 2A solution to two wells in every ELISA plate used to determine the
concentration ofENE 2A in various samples. This was also analysed by coefficient of
variance using the following equation:
Coefficient of variance = standard deviation/mean x 100
Evaluation of Sheep Anti-ENE 2A Antibody Recognition of Complexed ENE by
ELISA. ENE 2A in the free and complexed state was subjected to the ELISA
described above. To 200ng of purified ENE 2A (in lOOpl PBS) affinity purified API
(800ng in lOOpl PBS) was added and incubated for 30 minutes at room temperature
to allow formation ofENE 2A:API complex. An identical sample of 200ng of purified
ENE 2A was diluted with lOOpl of PBS to bring the concentration of free ENE 2A
equal to that of the complexed ENE 2A (200ng/200pl PBS). Each sample was further
diluted and applied to the above ELISA in triplicate at concentrations of 0.5-4.0ng/ml
ofENE 2A.
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Evaluation of the Amount of ENE 2A per Equine Peripheral Blood Neutrophil.
Peripheral blood leukocytes from 11 horses (6 mares, 4 geldings and 1 stallion,
median age 10 years, range 5-19 years) were purified as above and resuspended at
5xl06cells/ml. Diff-Quik™ stained cytospins were used to determine the percentage
of neutrophils in each of the Percoll purified preparations, 500 cell being counted
from random high power (x 1000) fields (Chapter 2.14). One millilitre samples were
taken from each sample and stored at -70°C then subjected to 5 rapid freeze/thaw
cycles to induce cell lysis. DNA and cell debris were removed by centrifugation
(13800 x g, 10 minutes at 4°C). ENE 2A content in each supernatant was estimated
using the ELISA. Supernatants were diluted between 1/250 to 1/32000 in
5%MPBST20. To determine the amount of ENE 2A per equine neutrophil the
following equation was used :
ENE 2A per neutrophil = ELISA value (ng/ml)/
(No. of cells per ml in supernatant x percentage neutrophils)
5.2.8 Evaluation of the Amount of Equine API per Equine Peripheral Blood
Neutrophil
The polyclonal sheep anti-equine API raised and characterised in this study (Chapter
3.2.) was used in an equine API specific ELISA with minor modifications to the
previously described protocol (Scudamore et al 1994). Essentially the method was
identical to that described above (5.2.7) except that the coating antibody (sheep anti-
equine API antibody) concentration was lpg/ml, and the blocking and diluting
solution consisted of 4.5% BSA in PBS containing 0.05% Tween 20. The conjugate
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was sheep anti-equine API antibody:HRPO prepared as described in Chapter 2.12.1
and diluted to lpg/ml. Affinity purified API was used to create the standard curve.
The same samples used to determine ENE 2A content per equine peripheral blood
neutrophil were used to determine the amount of equine API except the samples were
diluted from 1/10 to 1/1280 times in 4.5%BSA/PBS/T20.
5.3 Results
5.3.1 Purification ofENE 2A
ENE 2A was successfully purified from equine peripheral blood neutrophils using a
combination of ion-exchange and MW exclusion chromatography. Subsequent to ion-
exchange chromatography high and low MW contaminants were still present in the
sample when examined by silver stained 12% SDS-PAGE under reducing conditions
(Figure 5.1). Molecular weight exclusion chromatography resolved these
contaminants into three distinct peaks on HPLC (Figure 5.2). The result was ENE 2A





Figure 5.1 - Determination of protein purity by silver stained 12% SDS-PAGE under
reducing conditions after ion-exchange chromatography. Lane 1 contains MW
markers (kDa), lane 2 the purified protein. Note, ENE 2A (black arrow) is the major


















Figure 5.2 - Graph of absorbance versus time for MW exclusion chromatography
showing the resolution of the three distinct peaks of high (HMW) and low MW
(LMW) contaminants along with that of ENE 2A which enabled further purification










Figure 5.3 - Determination of ENE 2A purity by Coomassie brilliant blue (R-250)
stained 12% SDS-PAGE after MW exclusion chromatography. Lane 1, MW markers.
Lane 2, ENE 2A (arrow).
5.3.2 Isolation ofEquine Peripheral Blood Neutrophils
The purity of equine neutrophils isolated on a Percoll discontinuous gradient from 11
different horses was 96.5% ±3.0 (mean ± SD, n =11, Figure 5.4).
1 0f>
WVc-s?
Figure 5.4 - Percoll purified peripheral blood leukocytes stained with Diff-Quik (x
1000).
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5.3.3 Characterisation of the Sheep Anti-ENE 2A Antibody
Purified API isoforms and APEENE 2A complex had MW from 57-69kDa and 79-
108kE)a respectively (Figure 5.5), these ranges reflecting the differing MW of API
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Figure 5.5 - Coomassie brilliant blue (R-250) stained 10% SDS-PAGE under
reducing conditions comprising; MW markers, purified ENE 2A (0.5pg), neutrophil
extract (20pl), APEENE 2A complex (1.0pg:0.5pg respectively) and affinity purified
API (l.Oqg) in lanes 1-5 respectively. Note the higher MW of APEENE 2A complex
(lane 4) compared to native API (lane 5).
Western blots showed no cross reactivity between sheep anti-ENE 2A and sheep anti-
equine API antibodies to API or ENE 2A respectively in the reduced (Figure 5.6) or
non-reduced state (data not shown), yet both clearly recognised APEENE complex
(Figure 5.6). Further scrutiny of the specificity of the sheep anti-ENE 2A antibody
reveals that it identifies its target protein in the neutrophil extract despite the presence
of other proteins and also a band of 55kDa MW (Figure 5.6). On the azocasein gel
(Figure 5.7) proteolysis was absent in the equivalent area of this 55kDa MW band yet
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all uncomplexed ENE 2A found in lanes 2, 3 and 4 displayed proteolytic activity
which suggests the 55kDa band may be an elastase:inhibitor complex. Several studies
have reported the intracellular serpin. horse leukocyte elastase inhibitor (HLEI), to
have a MW of 35.2kDa (Dubin, 1977; Dubin and Koj, 1986; Potempa et al 1988),
hence the 55kDa band may represent ENE 2A complexed with HLEI. This complex is
stable in the presence of SDS under reducing conditions (Figure 5.6) unlike that of
secretory leukocyte proteinase inhibitor (SLPI), found in human neutrophils
(Sallenave et al 1997a), which can form complexes with HNE.
12 3 45 6789
Figure 5.6 - Western Blot of gel identical to that shown in Figure 5.5 in which lanes
2-5 are repeated in lanes 6-9. Lane 1 comprises Coomassie brilliant blue (R-250)
stained MW markers (kDa), lanes 2-5 probed with sheep anti-ENE 2A antibody and
lanes 6-9 probed with sheep anti-equine API antibody. Purified ENE 2A in lanes 2
and 6 (black arrow); neutrophil extract (lanes 3 and 7); APEENE 2A mixture (lanes 4
and 8); affinity purified equine API (red arrow, lanes 5 and 9). APEENE 2A complex
is detected with both anti-ENE 2A and anti-equine API antibodies (green arrows,
lanes 4 & 8). The 55kDa band in the neutrophil extract (blue arrow, lane 3) may
represent ENE 2A:HLEI complex.
Two bands of proteolysis of lower MW than uncomplexed ENE 2A were also
detected demonstrating the presence of other proteases in the neutrophil extract.
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Purified API demonstrates no proteolytic activity but the APEENE 2A complex
shows a trace amount (Figure 5.7).
1 2 3 4 5
Figure 5.7 - Coomassie brilliant blue (R-250) stained 10% SDS-PAGE under non-
reducing conditions with azocasein incorporated into the resolving gel to show
proteolysis. The loading is identical to that described for the gel in Figure 5.5. Note
proteolytic activity (denoted by clear bands) in lane 2 corresponding to purified ENE
2A (red arrow) and also at the same MW in lanes 3 and 4 (neutrophil extract and
APEENE 2A mixture respectively). Affinity purified API shows no proteolytic
activity as expected (lane 5). APEENE 2A complex show a small amount of
proteolytic activity (green arrow, lane 4). Two areas of proteolytic activity are seen at
lower MW than ENE 2A in the neutrophil extract (white arrows, lane 3).
5.3.4 lmmunolocalisation ofENE 2A in Peripheral Blood Leukocytes
Immunocytochemistry of a mixed population of equine peripheral blood leukocytes
with the sheep anti-ENE 2A antibody clearly demonstrates the presence ofENE 2A in
multiple cytoplasmic granules confined to neutrophils (Figure 5.8). All cell nuclei
were negative for ENE 2A (Figure 5.8). Negative control preparations were devoid of
immunostaining (Figure 5.9).
137
Figure 5.8 - Equine peripheral blood leukocytes labelled with sheep anti-ENE 2A
antibody, rabbit anti-sheep IgG:HRPO with AEC substrate (red pigment) showing
location of ENE 2A. Neutrophils (black arrows) are easily identifiable by their
multilobed nuclei and the abundant red granular staining cytoplasm. Eosinophils
(green arrow) and monocytes (blue arrows) are devoid of any immunostaining for
ENE 2A(x 1000).
Figure 5.9 - For control purposes normal sheep IgG was substituted for sheep anti-
ENE 2A antibody. The leukocytes (neutrophils denoted by black arrows, eosinophil
by green arrows and monocytes by blue arrows) are devoid of any immunostaining for
ENE 2A (x 1000).
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5.3.5 Evaluation of ENE 2A and API in Peripheral Blood Leukocytes by Dual
Immunofluorescence
Immunofluorescence of a mixed population ofperipheral blood leukocytes with sheep
anti-ENE antibody clearly demonstrated the presence ofENE 2A in multiple cytosolic
granules in neutrophils (Figure 5.10). Other cell types were negative for ENE 2A as
were all cell nuclei. In contrast a more uniform, less intense and non-granular pattern
of immunostaining was seen in the cytosol of neutrophils when probed with the sheep
anti-equine API antibody (Figure 5.11). Cytoplasmic staining of equine API is also
present in some mononuclear leukocytes. Double immunofluorescence emphasises the
contrasting patterns of distribution ofAPI and ENE 2A in the cytosol of neutrophils.
However, the two proteins do appear to patially colocalize within the cytoplasm of
the neutrophils at some points (Figure 5.12). Negative control preparations were
devoid of immunofluorescence.
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Figure 5.10 - Immunofluorescence of equine peripheral blood leukocytes with sheep
anti-ENE 2A:Cy3 confirms that ENE 2A is confined to neutrophil granules (white
arrows, x 1000).
Figure 5.11 - The same field as that shown in Figure 5.10 but the cells are detected
with anti-equine API.FITC labelled antibody. The cytoplasm of neutrophils is diffusely
and variably immunofluorescent for equine API (white arrows). The cytoplasm of a
mononuclear cell (blue arrow) also immunofluoresces for equine API (x 1000).
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Figure 5.12 - Dual immunofluorescence for Figures 5.10 and 5.11. Some neutrophils
show little equine API immunofluorescence (blue arrow). There is some degree of
colocalisation between ENE 2A and API in neutrophils that immunofluoresce for both
proteins (x 1000).
5.3.6 Evaluation of the Repeatability of the ENE 2A Specific Sandwich ELISA
Intra and inter-plate variations in quantification of ENE 2A by the polyclonal
sandwich ELISA as represented by coefficients of variance (described in 5.2.7) were
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Figure 5.13 - Graph of absorbance (Optical Density) versus concentration ofENE 2A
for the standard curve (mean ± maximum and minimum of 3 values) in the specific
ELISA to measure the latter. The curve was used to derive ENE 2A concentrations of
diluted samples whose optical densities gave ENE 2A values between l-3.5ng/ml.
5.3.7 Evaluation ofSheep Anti-ENE 2A Antibody Recognition ofComplexed ENE 2A
by ELISA.
ENE 2A was recognised by ELISA whether in the free or complexed state. Analysis
of the absorbance values by the Kruskal-Wallis test found no significant difference in
OD values between free or complexed ENE 2A (p = 0.07).
5.3.8 Determination of the Amount of ENE 2A and Equine API in a Peripheral
BloodNeutrophil
The specific polyclonal sandwich ELISAs were used to quantify the neutrophil
content of ENE 2A and equine API independent of any enzymatic or inhibitory
properties. The values per neutrophil were 0.813pg ± 0.179 and 0.021pg ± 0.011
(mean ± SEM) for ENE 2A and API respectively.
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5.4 Discussion
The original protein purification procedure (Dubin et al 1976) based on ion-exchange
chromatography resulted in relatively pure ENE 2A but with detectable high and low
MW impurities when subjected to silver stained SDS-PAGE (Figure 5.1) which were
easily removed by MW exclusion chromatography (Figure 5.2). The resultant ENE
2A («100% pure, Figure 5.3) was used to raise specific antibodies and as a ligand
both for affinity purification of specific antibody and as a standard curve for a
sandwich ELISA to measure ENE 2A. The MW of the purified ENE 2A (3 lkDa) as
determined by SDS-PAGE under reducing conditions is in agreement with that of a
recent study (Scudamore et al 1993).
The sheep anti-ENE 2A antibody is highly specific and recognises its antigen (ENE
2A) on Western blots and ELISA regardless of whether it is in the free or complexed
state (Figure 5.6). Monoclonal antibody IB also recognises its antigen (equine API) in
the free and complexed state when used to probe Western blots of immobilised
antigens, the combined results from the two antibodies can be used to identify ENE
2A:API complexes (Figure 5.6). The ability to recognise ENE 2A in the free or
complexed state to a similar degree is advantageous as this will result in measurement
of total ENE 2A by the ELISA in biological samples.
The presence of two separate bands of proteolysis on the azocasein gel (Figure 5.7),
both of lower MW than ENE 2A, suggests the presence of other proteolytic enzymes
in the neutrophil extract. ENE 2B is reported as having a lower MW than ENE 2A as
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well as a lower concentration per neutrophil (Dubin and Koj, 1986). One of these
bands denoting proteolysis may represent ENE 2B emphasising how immunologically
distinct from ENE 2A it is as no corresponding band is seen on the Western blot of an
identical gel probed with the sheep anti-ENE 2A antibody (Figure 5.6). The identity
of the third band of proteolysis found on the azocasein gel is unknown as the only
other proteolytic enzyme described in equine neutrophils is proteinase 1 which was
shown to have a higher molecular weight than ENE 2A (Dubin et al 1976; Potempa,
1982). No other proteolytic enzymes have been isolated from equine neutrophils.
Equine neutrophils have been reported to contain about one third the neutrophil
elastase found in human neutrophils (Dubin and Koj, 1986; Campbell et al 1989) and
this has been proposed as a possible explanation for the rarity of emphysema in the
horse (Edelman et al 1992). Using a specific sandwich ELISA we have shown the
amount ofENE 2A per neutrophil to be over 0.8 pg/cell which is 100% greater than
previous estimates derived by evaluation ofenzyme activity (Dubin and Koj, 1986). In
addition, equine neutrophils contain the immunologically distinct elastase, ENE 2B, at
approximately a third the concentration and 5 times the elastinolytic activity of ENE
2A (Dubin et al 1976) suggesting that the total amount ofENE per equine neutrophil
is even closer to the figure accepted for human neutrophils (1.1pg/cell) (Campbell et
al 1989). The presence ofHLEI (Dubin, 1977; Potempa et al 1988; Dubin et al 1992;
Kordula et al 1993) and API in equine neutrophils implies that measurement of ENE
by an immunological method, independent of enzyme activity, may be a more accurate
means of determining total elastase concentrations. On Western blots, the presence of
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a 55kDa band in horse neutrophil extract (Figure 5.6) which was detected with the
sheep anti-ENE 2A antibody but has no demonstrable proteolytic activity confirms the
presence of ENE 2A complexes (Figure 5.7). Human neutrophils are known to
contain endogenous inhibitors, notably API and secretory leukocyte proteinase
inhibitor (SLPI), the latter is more abundant and therefore probably the most
important cytosolic elastase inhibitor (duBois et al 1991; Sallenave et al 1997a). This
study has confirmed the presence ofAPI in equine neutrophils at a low concentration
(0.02pg/cell) indicating that it may similarly have a minor role to play as HLEI is
reported to be present at 0.5pg/cell (Dubin and Koj, 1986). The different distributions
of API and elastase in horse neutrophils also suggests that they do not completely
colocalise and therefore elastase is unlikely to be fully regulated by API. This is
supported by the lack of immunoreactive APEENE 2A complexes seen on Western
blots of crude neutrophil extracts despite the presence of the 55kDa band suggesting
this is a complex ofENE 2A (31kDa) and HLEI (35.2kDa) and not ENE 2A and API
which would have a molecular weight from 79-108kDa (Figure 5.6).
These results, contrary to the accepted figures, show that horses and humans have
similar concentrations of neutrophil elastase per peripheral blood neutrophil. In terms
of their respective elastinolytic activity, ENE 2B is reported to have seven times that
of HNE which has similar elastinolytic activity to that ENE 2A (Dubin and Koj,
1986), again suggesting that the overall elastinolytic potential between the two
species is similar.
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The ELISA developed in this study will be of great value in determining the relative
amounts of ENE 2A released from Percoll purified equine peripheral blood
neutrophils stimulated with secretagogues under various conditions.
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Chapter 6
KINETICS OF EQUINE NEUTROPHIL ELASTASE 2A
RELEASE AND SUPEROXIDE ANION GENERATION
FOLLOWING ACTIVATION BY ZYMOSAN ACTIVATED
SERUM
6.1 Introduction
Equine neutrophils have been shown to significantly differ in their functional
responses to various stimuli in comparison to neutrophils from other species (Styrt,
1989). Reduced release of superoxide anion radicals (SOA) is seen in equine
neutrophils stimulated with N-formyl-methionyl-leucyl-phenylalanine (fMLP)
compared to humans neutrophils (Brazil et al 1998). This is thought to be due to
equine neutrophils having fewer receptors with a single affinity for fMLP (Snyderman
and Pike, 1980) compared to human neutrophils which have more cell surface fMLP
receptors and of two differing affinities (Snyderman and Goetzl, 1981; Snyderman
and Pike, 1984; Snyderman, 1984). Furthermore, equine neutrophils, in contrast to
human neutrophils, equine eosinophils and porcine granulocytes, are unable to
produce leukotrienes when stimulated solely with the calcium ionophore A23187
(Lindberg et al 1998). However, addition of exogenous arachidonic acid along with
ionophore to purified equine peripheral blood neutrophils results in the production of
leukotriene B4 suggesting that elevation of intracellular calcium is insufficient in itself
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to induce utilisation of endogenous arachidonic acid from cell membranes in horse
neutrophils (Lindberg et al 1998).
The most consistent chemotactic response across the species appears to be to
activated homologous plasma or serum (reviewed in Styrt, 1989). The complement
fragment C5a is presumed to be the major active component in activated serum or
plasma, but other factors or complement fragments may also play a role. This
suggests that there is a receptor for complement fragments on neutrophils of all the
mammalian species so far studied; human, non-human primate, equine, bovine, feline,
rabbit, guinea pig, mouse and rat (reviewed in Styrt, 1989).
There are however marked species differences in response to other chemotaxins. For
example equine neutrophils have been shown to be unresponsive to equine API:ENE
2A complex (Scudamore et al 1993), the human equivalent being highly chemotactic
for human neutrophils (Banda et al 1988). Neutrophil chemotaxis to fMLP, which has
been well characterised, is also species dependent; primate, rat, rabbit and guinea pig
neutrophils all respond chemotactically to fMLP whereas porcine, feline, canine and
equine neutrophils do not (reviewed in Styrt, 1989). However, fMLP can induce
equine neutrophils to secrete lysosomal enzymes (Camp and Leid, 1982; Sedgwick et
al 1987; Fittschen et al 1988; Mcewen and Lumsden, 1991). The presence of a single
type of fMLP receptor on the equine neutrophil (Snyderman and Pike, 1980) has
again been proposed as a possible explanation for this difference as stimulation of
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different fMLP receptors on human neutrophils may induce different cellular
responses (Styrt, 1989).
Human neutrophils have been shown to release HNE and SOA concurrently when
stimulated with either fMLP, phorbol-myristate-acetate (PMA) or the calcium
ionophore A23187 (Khalfi et al 1998). Interestingly, opsonised zymosan (OZ), which
induces a respiratory burst, does not induce human neutrophils to degranulate and
release HNE (Khalfi et al 1998) suggesting a different stimulatory mechanism or
pathway compared to fMLP, PMA and A23187. Inhibition of protein kinase C (PKC)
prior to stimulation of human neutrophils with PMA, dioctanoylglycerol, fMLP,
calcium ionophore A23187 or OZ significantly abrogates the production of SOA
suggesting this enzyme is critical to the process (Cabanis et al 1996). However,
inhibition of PKC only appears to abrogate PMA mediated elastase release, not that
induced by fMLP and A23187 (Cabanis et al 1996). This suggests that fMLP and
A23187 do not mediate elastase release through PKC despite producing a similar
SOA response compared to PMA. Contrary to the human scenario (Khalfi et al
1998), buffalo neutrophils release NE when stimulated with OZ (Singh et al 1997)
illustrating further species variations in the functional responses to identical stimuli.
Unregulated and/or excessive elastase activity has been shown to be responsible for
pulmonary emphysema in all species so far studied (Laurell and Eriksson, 1963; Hayes
et al 1975; Janoflf et al 1977; Janoflf et al 1979; Janoflf, 1985a) yet specific
measurement of NE released from stimulated equine neutrophils has not been
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previously documented. The main inhibitor of NE in the lower respiratory tract of
humans is API (Gadek et al 1981a) which has been shown to be oxidatively
inactivated in vitro by SOA from stimulated human neutrophils (Matheson et al 1981;
Ras et al 1992). Inactivation of API could lead to an increase in half-life of free NE
secreted into the microenvironment around activated neutrophils (Johnson and Travis,
1979; Matheson et al 1982). For this proposed synergism to occur there must be
some temporal relationship between the release of these two neutrophil products.
Species differences in functional responses to various stimuli highlight the need to
study neutrophils specifically from the species of interest and to extrapolate with
caution from the data for other species. Differences between equine and human
neutrophils with respect to SOA generation and release ofNE in terms of response to
various stimuli and temporal co-ordination of these responses may affect the relative
proteinase:antiproteinase balance resulting in species variations in susceptibility and
development of pulmonary emphysema.
The aims of this study were to investigate the characteristics of ENE 2A release and
of SOA generation from equine peripheral blood neutrophils stimulated with zymosan
activated serum (ZAS). The dependence of these processes on extracellular divalent
cations was also investigated in an attempt to elucidate the mechanism through which
the ZAS stimulus was mediated.
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6.2 Materials and Methods
6.2.1 Preparation ofZymosan Activated Serum
Zymosan activated serum was used as a source of the complement fragment C5a.
Serum was chosen as opposed to plasma as clotting of the latter interfered with the
sampling procedure for evaluation of ENE 2A release from stimulated neutrophils
(see below). Serum was prepared by restoring calcium to platelet rich equine plasma
(a by-product of the neutrophil purification procedure, see Chapter 5.2.2) by addition
of 220pl of lOmM CaCl/lOml followed by incubation for 90 minutes at 37°C in an
humidified 5% CO2 atmosphere. Zymosan was mixed with the serum (5mg/ml) by
vortexing and sonication. When all the zymosan was suspended, the mixture was
incubated at 37°C for 60 minutes followed by centrifiigation at 1400 x g for 15
minutes and by separation of the supernatant from the insoluble zymosan pellet. Heat
inactivated zymosan activated serum (HIZAS) was produced by an identical
procedure except that the serum was heat inactivated at 56°C for 30 minutes before
addition of zymosan. Both supernatants were stored in aliquots at -70°C.
6.2.2 ZAS Stimulation ofSOA Generation
A sample of the Percoll purified peripheral blood neutrophils, isolated as described in
Chapter 5.2.2, was resuspended at 12.5 x 106 cells/ml in Dulbecco's PBS/0.1% BSA
at 37°C. Detection of extracellular SOA was by lucigenin-dependent
chemiluminescence (LDCL) (Allen, 1986; Benbarek et al 1996) using a ML 3000
microtitre plate luminometer (Dynex Technologies, Billingshurst, West Sussex, UK).
lOOpl lucigenin (0.25mM in Dulbecco's PBS/0.1% BSA at 37°C) and 1 x 106 freshly
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isolated cells (80pl) were added to each well. After a 5 minute equilibration phase,
basal LDCL was recorded over 12 minutes to ensure that cells were not basally
activated. A dose response curve was derived for SOA generation in response to ZAS
stimulation; 20pl of either undiluted ZAS, or doubling dilutions of ZAS with
Dulbecco's PBS/0.1% BSA (1/2, 1/4 and 1/8), were used to stimulate SOA release
from Percoll purified equine peripheral blood neutrophils (5 x 106 cells/ml final
concentration), samples were performed in triplicate (n = 1 individual horse). After
determination ofoptimal stimulation, experiments were performed by addition of 20pl
of buffer (PBS), undiluted ZAS, HIZAS or ZAS + EGTA (final cone. EGTA 4mM).
Basal and agonist stimulated chemiluminescence were recorded to produce mean peak
and integral (area under the curve) chemiluminescence values over a 90 minute period
for 6 individual horses.
6.2.3 ZAS Stimulation ofENE 2A Release
The remaining purified neutrophils were resuspended at 5.56 x 106 cells/ml in
Dulbecco's PBS /0.1% BSA and 4.5ml aliquots placed in universal containers. A dose
response curve was derived for release of ENE 2A from Percoll purified peripheral
blood neutrophils in response to ZAS stimulation. Undiluted ZAS (0.5ml) or doubling
dilutions of ZAS with Dulbecco's PBS/0.1% BSA (1/2, 1/4 and 1/8) were added to
stimulate ENE 2A release from the neutrophils and the concentrations measured by
the ELISA described in chapter 5.2.7 (n = 1 individual horse). After determination of
the stimulation required for optimal release of ENE 2A, experiments were performed
by addition of 0.5ml of either PBS, undiluted ZAS, HIZAS or ZAS with EGTA (final
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conc. EGTA 4mM) to separate identical universal containers, into which 4.5ml of
purified neutrophils had already been placed. This gave a final cell concentration of 5
x 106 cells/ml and was followed by gentle mixing. Samples (0.5ml) were withdrawn at
0, 15, 30, 45, 60, 90, 120 and 150 minutes. Each sample was centrifiiged at 13800 x g
for 10 minutes at 4°C, the supernatant was decanted and stored at -70°C until analysis
by ELISA for ENE 2A concentration as described in chapter 5.2.7 (n = 6 individual
horses).
6.2.4 Cell Viability
Cell viability was assessed by trypan blue exclusion (Chapter 2.14) at time zero and
150 minutes post stimulation for samples exposed to each of the four stimuli.
6.3 Results
6.3.1 Dose Response Curves
Superoxide Anion Generation. Undiluted ZAS produced the maximum generation of
SOA as detected by LDCL with a peak at 35 minutes post stimulation and abrogation
of the response by 90 minutes. The response was markedly attenuated by a two fold
dilution ofZAS and further reduced by four and eight fold dilutions (Figure 6.1). PBS
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Figure 6.1 - Dose response curve of SOA generation from Percoll purified equine
peripheral blood neutrophils with doubling dilutions of ZAS as detected by lucigenin
dependent chemiluminescence (LDCL) measured in relative light units (RLU). Values
are mean of triplicate wells. Note maximal generation ofSOA by undiluted ZAS.
ENE 2A Release in Response to ZAS. Undiluted ZAS stimulated the maximal release
ofENE 2A with the dilutions ofZAS (1/2, 1/4 and 1/8) resulting in progressively less
ENE 2A being released (Figure 6.2). Increases were noticeable at 60 minutes but
much greater by 120 minutes. After 60 minutes neutrophils treated with PBS show
some 'leakage' of ENE 2A which could be due to suboptimal media for maintaining









Figure 6.2 - Dose response curve of ENE 2A release from Percoll purified equine
peripheral blood neutrophils with doubling dilutions of ZAS as detected by ELISA.
Note the undiluted ZAS gave the maximal release ofENE 2A.
6.3.2 Concurrent Generation ofSOA and Release ofENE 2A From ZAS Stimulated
Equine Peripheral blood Neutrophils
Undiluted ZAS produced the largest generation of SOA and release ofENE 2A from
Percoll purified equine peripheral blood neutrophils and was used as a stimulus in all
subsequent experiments. The ZAS induced respiratory burst produced a peak SOA
generation at 25 minutes post stimulation with complete desensitisation of the
response by 90 minutes despite the continued presence of the agonist (Figure 6.3).
Comparison of the total amount of SOA produced over 90 minutes, as represented by
the areas under the curves, show that a statistically significant greater quantity of
SOA was generated by neutrophils stimulated with ZAS when compared (Kruskal-
Wallis test) to the amounts generated in response to the other three stimuli (ZAS vs.
HIZAS p = 0.01, ZAS vs. PBS p = 0.005 and ZAS vs. ZAS + EGTA p = 0.005).
Stimulation with HIZAS resulted in similar kinetics for SOA generation but with a
significant reduction in magnitude (ZAS vs. HIZAS p = 0.01). Cells stimulated with
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PBS or ZAS + EGTA released negligible levels of SOA. Zymosan activated serum
stimulation in the presence of EGTA abolished the SOA generation such that the
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Figure 6.3 - SOA generation from ZAS, HIZAS, ZAS+EGTA and PBS stimulated
equine neutrophils detected by LDCL (relative light units, RLU, mean ± SEM of 6
individual horses) over 90 minutes. Note peak of SOA generation in both ZAS and
HIZAS is at 25 minutes post stimulation and total abrogation of response occurs by
90 minutes.
In contrast, the kinetics of ENE 2A release (in response to ZAS stimulation) were
prolonged with continuing accumulation in supernatants for up to 150 minutes (the
final sampling point, Figure 6.4). ZAS stimulated neutrophils consistently released
significantly greater amounts ofENE 2A over the whole 150 minutes (when analysed
by Kruskal-Wallis test) compared with values for PBS (p = 0.005). However, the
ENE 2A released after stimulation with ZAS is significantly greater than that
generated in the presence of HIZAS over the first 90 minutes (p = 0.03-0.005).
Interestingly, EGTA did not completely abrogate ENE 2A release in response to ZAS
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as there is no statistical difference from ZAS treated cells in the amount ofENE 2A at
time zero (p = 0.1). The amount ofENE 2A released from neutrophils stimulated with
ZAS + EGTA varies very little from the initial value at time zero suggesting that there
is little or no release of ENE 2A after this. Over the initial 90 minutes there is a
significant difference between the amount of ENE 2A released from neutrophils
treated with ZAS + EGTA and those treated with PBS (p = 0.03-0.005). By 120
minutes the 'leakage' of ENE 2A from cells treated with PBS has risen to a level
whereby the difference between the two stimuli is no longer significant (p = 0.07).
Figure 6.4 - Cumulative release of ENE 2A from Percoll purified equine peripheral
blood neutrophils stimulated with ZAS, HIZAS, ZAS+EGTA and PBS, mean ± SEM
of 6 individual horses. Note different characteristics of release pattern compared to
SOA generation (Figure 6.3) and the consistently higher concentration of ENE 2A in
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Figure 6.5 - Comparison of the levels of SOA and ENE 2A over 150 minutes post
stimulation of equine neutrophils by ZAS. Note rapid burst of SOA compared to
slower and more prolonged release ofENE 2A.
6.3.3 Cell Viability
Cell viability, as denoted by trypan blue exclusion, was 100% (n = 6 for each of the
four stimuli) at time zero in all four stimuli. At 150 minutes post stimulus mean cell
viability in all cases was still > 99%.
158
6.4 Discussion
The presence of complement fragment receptors on the surface of neutrophils from
previous chemotactic studies in all mammalian species so far examined (Styrt, 1989),
including horses (Scudamore et al 1993) suggested that activated complement plays a
major role in neutrophil stimulation in vivo. This prompted the choice of ZAS in this
study to evaluate the effect of a single stimulus on concurrent SOA generation and
release ofENE 2A from equine neutrophils.
The relationship between total SOA generation and total ENE 2A release during the
initial 90 minutes post ZAS stimulation (the duration of the oxidative burst) suggests
that the extra-cellular release of the two products are closely linked, however, the
kinetics of release are markedly different. Superoxide anions are generated and
released in a respiratory burst lasting about 90 minutes with a peak at 25 minutes. In
contrast elastase release is initiated at the start of the oxidative burst and then
continues to accumulate at a steady rate leading to a nearly linear increase in the
extracellular concentration for at least 150 minutes post ZAS stimulation. Human API
and equine Spil are oxidation sensitive due to the presence of methionine residues at
critical positions in the API molecules. The early peak of superoxide anion release
may act to down regulate serpin inhibition of elastase activity in the extracellular
micro-environment of the neutrophil by reducing API's KaSS and Ki with neutrophil
elastase (Cohen, 1979; Nakajima et al 1979; Beatty et al 1980; Travis et al 1980;
Hubbard et al 1987; Potempa et al 1991b; Snider, 1992; Buhl et al 1996).
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These findings indicate that, while there may be a common signalling pathway
initiating superoxide anion and elastase release (Roos, 1991), the post initiation
mechanisms of release are clearly different. Superoxide anion is known to be
generated by NADPH oxidase which can become refractory despite continued
presence of the stimulus (Rossi, 1986; Roos, 1991). However, elastase release does
not appear to be refractory to continued presence of the stimulus throughout the time
course of these experiments. The continued presence of the stimulus may mimic the in
vivo situation where inflammatory stimuli and mediators may be present in the tissue
for many minutes or hours. It is possible that this results in release of neutrophil
elastase over a prolonged time period which with early superoxide anion assistance
produces persistent low levels of proteolysis resulting in tissue damage. Interestingly,
less than 10% of the total elastase content of equine neutrophils was released over the
initial 90 minutes when the SOA respiratory burst is present suggesting that either not
all of the ENE 2A present within equine peripheral blood neutrophils can be released
or, that the majority is released after the respiratory burst. Synergy between SOA and
ENE 2A would only be expected to occur in the initial 90 minutes post neutrophil
stimulation when SOA are oxidatively inactivating API and for a short period of time
afterwards until active API diffused into the area. This assumes that this in vitro
situation represents what occurs in vivo. However, recent data (Mark Dagleish,
preliminary study), has shown that the type of medium which the neutrophils are
suspended in greatly affects the cells' SOA generating capacity. Media such as
Iscove's modified Dulbecco's medium (IMDM) increases the amount of SOA
generated and the time scale over which it is detected by LDCL compared to
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Dulbecco's PBS when an identical secretagogue is used. This suggests that a more
nutrient rich environment may enhance the amount and duration of the respiratory
burst of stimulated neutrophils resulting in an increased time period of synergy
between SOA generation and ENE 2A. The latter may be more representative of the
in vivo situation where neutrophils would be bathed in extracellular tissue fluid.
It is intriguing that heat inactivation of ZAS does not completely remove its ability to
stimulate neutrophil degranulation or SOA generation suggesting that there must be
some stimulus present other than heat labile C5a. However, the heat labile
components ofZAS do have a significant effect on the initial rate of degranulation and
release of ENE 2A (p = 0.005) compared to HIZAS (Figure 6.4). Further studies are
required to determine the exact nature of this heat resistant component.
Previous studies have shown SOA generation and HNE release from human
neutrophils to be variably dependent on extracellular divalent cations, the
concentration and the stimulus used (Khalfi et al 1996). SOA generation from human
neutrophils is dependent on extracellular calcium when stimulated by fMLP but not
when stimulated by PMA or OZ (Khalfi et al 1996). Elastase release from stimulated
human neutrophils is more complicated. PMA stimulation is independent of calcium
when the extracellular concentration ranges from zero to l.OmM, but dose dependent
from 1.5-4.0mM; greater concentrations of calcium resulting in more HNE release
(Khalfi et al 1996). Conversely, fMLP induced HNE release is dependent upon
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extracellular calcium from zero-1.5mM yet less affected at concentration greater than
1.5mM (Khalfi et al 1996).
In our study we found that the addition of EGTA abolishes ZAS stimulated
superoxide anion generation suggesting that this response must be dependent on
extracellular calcium and/or magnesium typical of a receptor mediated, secondary
messenger signalling mechanism (Korchak et al 1984; Buhl et al 1994) and similar to
fMLP stimulated human neutrophils (Khalfi et al 1996). However, ZAS-stimulated
ENE 2A release from equine neutrophils does not appear to be entirely dependent
upon extracellular calcium and/or magnesium. At the first time point the ENE 2A
content of supernatant from ZAS + EGTA stimulated cells is the same as the initial
ZAS stimulated value, which is significantly greater (p = 0.005) than that of the PBS
control. This suggests a small degree of cation independence, utilisation of stored
intracellular cations or a significant difference in the kinetics of ZAS stimulation
compared to chelation of cations by EGTA to facilitate initial release. This
phenomenon requires further study as human neutrophils have been shown not to
require a cytosolic calcium transient for degranulation or oxidative burst when
stimulated by some receptor mediated stimuli (IgG, Seetoo et al 1997).
The presence of significant levels of ENE 2A in some samples (ZAS and ZAS +
EGTA) at time zero (Figure 6.4) is probably due to the time taken from addition of
the stimulus to removal and storage of the supernatant after centrifugation at 4°C
allowing some cellular response.
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The absence of panacinar emphysema in horses with COPD (Kaup et al 1990),
despite a pulmonary neutrophilia (Freeman et al 1993; Dixon et al 1995a), a
comparable NE content to human neutrophils (Chapter 5) and concurrent temporally
related release of SOA and ENE 2A in response to a physiological stimulus still needs
to be addressed. Alpha-1-proteinase inhibitor is believed to be responsible for anti-
elastase activity at the alveolar level (Flubbard et al 1989; Ohlsson, 1980). In contrast
to human API, equine API contains oxidation resistant isoforms (Spi2, 3 & 4) which
may be resistant to superoxide anion inactivation (Patterson and Bell, 1989; Potempa
et al 1991b). Therefore the more abundant oxidation resistant Spi proteins in the
horse may result in API with full inhibitory activity towards ENE 2A in the presence
of SOA generation unlike the human scenario where all API is oxidation sensitive.
Alternatively equine neutrophils, despite pulmonary sequestration, may not be





Genetically depressed plasma API concentrations and their link with premature
pulmonary emphysema in humans (Laurell and Eriksson, 1963) was the discovery that
prompted extensive scientific research into this field of medicine. Despite large
numbers of affected patients, the disease defied rational investigation after its initial
discovery due to a poor understanding of the biochemistry and genetics of the
condition. Thirty years later, human API deficiency can now be diagnosed prenatally
(Cox, 1989) and potentially supplemented postnatally with purified proteins from the
milk of sheep transfected with the human API gene (Wright et al 1991; Carver et al
1993) thereby ameliorating the otherwise inevitable progressive destruction of lung
tissue.
Research into equine API was primarily initiated by the discovery that the horse was
the only animal, besides man, to suffer from what was originally termed 'spontaneous
pulmonary emphysema'. The horse was consequently proposed as a possible animal
model for further investigation into human pulmonary emphysema (Gillespie and
Tyler, 1969; Gerber, 1973). However, biochemical studies uncovered a host of
differences between human and equine API (Patterson et al 1991; Potempa et al
1991b) that, along with species differences in the anatomical pattern of tissue
destruction present in neutrophil associated emphysema (Kaup et al 1990; Creagh and
Krausz, 1992), has since excluded the use of the horse as an animal model (reviewed
in Chapter 1).
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This study has investigated some aspects of equine API and its target proteinase ENE
2A in an attempt to establish if a difference in the equine proteinase:anti-proteinase
balance may be responsible for the species difference in anatomical distribution of
tissue destruction in pulmonary emphysema in humans and horses.
Detection of equine API in the liver, using immunohistochemistry, suggests that API
is more abundant when compared to levels detected in normal human hepatocytes
(Palmer et al 1974; Palmer and Wolfe, 1976; Ray et al 1977; Palmer et al 1977; Ray
and Desmet, 1978). This may represent more abundant synthesis in the horse and
could be the reason for the higher plasma concentration of equine API (3.5-4g/l,
Patterson et al 1991) compared to that of humans (l-1.3g/l, Carrell, 1986).
Interestingly, the mouse, with 3.5-5g/l ofplasma API (Takahara and Sinohara, 1982),
has a distribution of API in hepatocytes (Gauldie et al 1980) which is similar to that
described in the horse. This suggests that hepatic immunolocalisation may purely
reflect the level of hepatic synthesis and consequent plasma levels of API. However,
in rats, which have a plasma API concentration close to that of humans (1.7g/l, Koj et
al 1978), hepatocytes are all positive for API in normal livers (Lamri et al 1986).
An alternative explanation is that there are methodological differences in the various
studies. This is supported by the findings of Feldmann et al, 1976, where, like the
present and the rat liver studies (Lamri et al 1986), paraformaldehyde was used as a
fixative. This was the only record of API being detected by immunohistochemical
165
means in hepatocytes from normal PiMM human liver biopsies. All of these data
support the theory that methodology is a key factor in successful immunodetection of
API in normal hepatocytes. The immunohistochemical detection of API in human,
mouse and rat tissues did not involve an antigen recovery procedure, as in the present
study, suggesting that this may be responsible, in part, for the even more extensive
staining ofAPI in equine liver tissue.
Direct evidence of hepatic synthesis of equine API has not yet been shown. However,
the diffuse staining of equine API in the cytoplasm of hepatocytes and the granular
inclusions, which were often found in the perinuclear region (Chapter 4.3.2), are
highly suggestive of synthesis in the endoplasmic reticulum followed by post
translational modification in the Golgi complex prior to secretion. Intense staining of
equine API in the bile ductules is consistent with the highly conserved C-terminal
peptide of the API molecule being hydrophobic which is thought to be responsible for
its association with various bile salts in humans, the precise role of this association is
still under investigation (Eriksson, 1996).
With the exception of the liver, no significant disparity in the distribution or the
cellular content of API was found between human and equine tissues. This would
suggest a similarity of tissue functions for API in both species despite the different
biochemical properties of equine and human API.
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Earlier studies suggested that the elastase content of an equine neutrophil was
considered to be about a third (Dubin and Koj, 1986) that of a human neutrophil
(Tetley et al 1989) and consisting mainly of a type that has similar elastinolytic
activity to HNE (Dubin and Koj, 1986). However, this study has emphasised the
importance of methodology when investigating enzymes and their inhibitors,
especially if there is any degree of colocalisation of the two in the tissues from which
they are purified. With the aid of immunological techniques it has now been shown
that the equine neutrophil contains over twice as much ENE 2A as previously
calculated. The lack of analysis of ENE 2B, independent of enzymatic activity, is an
important piece of the overall picture which needs to be addressed. Until this data,
along with those of release characteristics, are available a true comparison of
elastinolytic potential between equine and human neutrophils cannot be made.
At present all that can be surmised is that there is far more elastase present in an
equine neutrophil than was originally thought. The published relative elastinolytic
activity of ENE 2B being seven times greater than HNE, which in turn has similar
elastinolytic activity to ENE 2A need to be re-evaluated after careful purification and
kinetic studies using modern techniques.
Evidence of oxidative inactivation of human API is extensive (Cohen, 1979; Johnson
and Travis, 1979; Travis et al 1980; Beatty et al 1980; Matheson et al 1982; Beatty et
al 1984; Hubbard et al 1987). However, some question its occurrence in vivo
(Campbell et al 1982) suggesting that API is excluded from the immediate micro-
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environment, the neutrophil membrane forming a protective enclave for the released
HNE and SOA. Despite studies showing actual oxidative inactivation ofAPI by SOA
from activated neutrophils (Ossanna et al 1986; Padrines et al 1989; Ottonello et al
1992; Ras et al 1992) and alveolar macrophages (Hubbard et al 1987) in vitro there
has been little published data on the kinetics of concurrent extracellular detection of
SOA and NE from neutrophils stimulated with physiological stimuli. Equine
neutrophils have been shown in this study to generate and release SOA and secrete
ENE 2A into the extracellular milieu in a correlated manner that would suggest the
possibility of synergy and the potential for host tissue damage. Synergy is likely in the
initial 90 minutes post stimulation with ZAS in vitro, whereas, in vivo, this may occur
over a longer period due to the possibility of greater and prolonged SOA generation
when cells are bathed in tissue fluid.
API regulates and protects against the barrage of SOAs and against ENE 2A in the
lower respiratory tract in the horse. Not only is the concentration of equine serum
API (Patterson et al 1991), and consequently by diffusion the concentration of
pulmonary API, greater than that of humans (Carrell, 1986), but some equine API
isoforms are resistant to oxidative inactivation (Patterson et al 1991). The majority of
the oxidation resistant APIs (Spi3A and B) have a KaSS at least two orders of
magnitude less than that the oxidation sensitive Spil (Potempa et al 1991b; Alan
Pemberton, unpublished data). This in itself could be critical as total abolition of
extracellular NE activity would be disadvantageous to host defence. People suffering
from Chediak-Higashi syndrome have defective neutrophils and are prone to
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persistent bacterial infections (Dale et al 1972). It must be borne in mind that
although we are investigating host tissue damage by neutrophils, they, and their
microbicidal products are essential to host defence and ultimately survival.
The role of oxidation sensitive API as an inhibitor of SOA activity has not been
investigated but it has the potential to play a significant role as an antioxidant for
scavenging free radicals and thereby protecting host tissues. The importance ofAPI as
an antioxidant in pulmonary tissues needs to be considered more broadly rather than
confining research purely to oxidative inactivation ofAPI.
In conclusion this study, together with the previously published data, suggest that
equine and human neutrophils contain comparable amounts of NE. Stimulation of
neutrophils by ZAS results in extracellular SOA and ENE 2A which have the potential
to act synergistically over the initial 90 minutes post-stimulation in vitro and probably
longer in vivo. The differences in the degree and anatomical distribution of pulmonary
emphysema in horses and humans is probably due to a more effective anti-elastase
screen provided by a higher concentration of equine API in pulmonary epithelial lining
fluid, derived from the plasma, combined with the presence of oxidation resistant Spi
proteins resulting in more efficient inhibition of extracellular ENE in the neutrophil
microenvironment. The horse, in having a plasma concentration of oxidation sensitive
Spil comparable to that of humans, as well as oxidation resistant Spi proteins, has
probably achieved a more efficient anti-elastase screen.
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The evolutionary forces behind the horse developing a more efficient antiproteolytic
screen are less than obvious. The wild horse originally inhabited several differing
environments; tundra, moorland, marsh and forest etc. (Bennet, 1992), none of which
would appear to subject the horse to greater proteolytic or pulmonary inflammatory
inducing conditions than those experienced by early humans.
However, we may be looking at this the wrong way. What if there has been a
selection pressure against humans having a high antiproteinase screen? Support for
this theory comes from examination of the PiZ homozygous state in humans where
the frequency of the Z gene is far too high to be present just by chance (Kueppers,
1972). This suggests there must have been some positive selection pressure for a less
potent antiproteolytic screen. The most likely explanation for a higher gene
prevalence would be if it affected fertility in a positive manner. One study found a
proteinase in rabbit sperm that was inhibited by API and suggested that if it occurred
in humans, sperm would be more able to penetrate the zona pellucida of ova in homo
and heterozygotes for the PiZ allele resulting in greater fertility compared to PiMM
individuals (Kueppers, 1972).
Another possible explanation for depressed API levels resulting in increased fertility in
PiZ homo and heterozygotes could be species variations in placentation. Humans have
haemochorial placentas compared to the epitheliochorial placentas of the horse
(reviewed in Wooding and Flint, 1994). The main differences between the two
systems being the amount of invasiveness at implantation of the fertilised egg and the
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intimacy of maternal and foetal blood supplies. In the horse, the uterine epithelium
and conceptus come into contact and placental development essentially involves a vast
increase in area with no loss of any tissue layers between the foetal and maternal
bloodstreams. However, human placentation involves the conceptus rapidly intruding
through the uterine epithelium into the endometrium followed by considerable
decidual development to reduce the distance between foetal and maternal blood
microflows to 4pm compared to 5-10pm in the horse (reviewed in Wooding and
Flint, 1994). Details of the actual process by which the human conceptus gains entry
to the endometrium are not known but it is not unreasonable to assume some
proteolytic mechanism may play a part. Humans with a high antiproteolytic screen
would thus be less fertile as the chances of successful implantation of the conceptus
would be reduced. Interestingly, rats have the same type of placenta and a similar
plasma concentration ofAPI to humans (1.7 and 1.3g/l respectively).
Hence the reason for the difference in antiproteolytic screen between humans and
horses may be due to the differences in placentation with the increased susceptibility
to pulmonary emphysema being the cost humans have to pay for successful
reproduction and our present longevity.
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APPENDIX 1






Dissolve in 1 litre de-ionised, distilled water and adjust pH to 7.2-7.3
ENE 2A and Equine API ELISA Coating Buffer
1.59g Na2C03
2.93G NaHC03
Dissolve in de-ionised, distilled water and make up to 1 litre. Adjust pH to 9.6 (if










Serum Free Culture Media
Serum free culture media consisted of the following mixture:
RPMI 1640 with 20mM HEPES, 0.85g/l sodium bicarbonate
2mM L-glutamine
Penicillin/Streptomycin solution (100 units/ml and 100 pg/ml respectively)
Screening of Foetal Calf Serum
Samples of foetal calf serum (FCS) should be obtained from various suppliers noting
batch number, batch size, price and length of holding time. Prepare 15% FCS/RPMI
1640 medium (as above) with various FCS and sterility check. Cell lines to be tested
are then diluted out to one cell per well of a 96 well plate and incubated at 37°C in an
humidified incubator with 5% CO2 and checked on day 5-7 for growth of cells,
followed by feeding and rechecking in 3 days. Antibody production from hybridoma
cell lines is assessed as in Chapter 3.2.3. Serum is selected on the basis of cell growth,
antibody titre and price.
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